Background  ||| S:24 E:43 ||| NN
In  ||| S:43 E:46 ||| IN
this  ||| S:46 E:51 ||| DT
investigation ||| S:51 E:64 ||| NN
,  ||| S:64 E:66 ||| ,
we  ||| S:66 E:69 ||| PRP
explored  ||| S:69 E:78 ||| VBD
the  ||| S:78 E:82 ||| DT
potential  ||| S:82 E:100 ||| JJ
cytotoxic  ||| S:100 E:110 ||| JJ
interaction  ||| S:110 E:122 ||| NN
between  ||| S:122 E:130 ||| IN
LPS  ||| S:130 E:134 ||| NNP
and  ||| S:134 E:138 ||| CC
CEES  ||| S:138 E:143 ||| NNP
using  ||| S:143 E:149 ||| VBG
a  ||| S:149 E:151 ||| DT
murine  ||| S:151 E:166 ||| JJ
macrophage  ||| S:166 E:177 ||| JJ
cell  ||| S:177 E:182 ||| NN
line  ||| S:182 E:187 ||| NN
( ||| S:187 E:188 ||| -LRB-
RAW264.7 ||| S:188 E:196 ||| NNP
) ||| S:196 E:197 ||| -RRB-
.  ||| S:197 E:199 ||| .
CEES  ||| S:199 E:204 ||| NNP
is  ||| S:204 E:207 ||| VBZ
a  ||| S:207 E:209 ||| DT
monofunctional  ||| S:209 E:232 ||| JJ
analog  ||| S:232 E:239 ||| NN
of  ||| S:239 E:242 ||| IN
sulfur  ||| S:242 E:249 ||| JJ
mustard  ||| S:249 E:257 ||| NN
( ||| S:257 E:258 ||| -LRB-
bis-2- ||| S:258 E:264 ||| NNP
( ||| S:264 E:265 ||| -LRB-
chloroethyl ||| S:265 E:276 ||| LS
) ||| S:276 E:277 ||| -RRB-
sulfide ||| S:277 E:284 ||| NN
)  ||| S:284 E:286 ||| -RRB-
which  ||| S:286 E:300 ||| WDT
a  ||| S:300 E:302 ||| DT
bifunctional  ||| S:302 E:315 ||| JJ
vesicant  ||| S:315 E:324 ||| NN
and  ||| S:324 E:328 ||| CC
a  ||| S:328 E:330 ||| DT
chemical  ||| S:330 E:339 ||| NN
warfare  ||| S:339 E:347 ||| NN
agent ||| S:347 E:352 ||| NN
.  ||| S:352 E:354 ||| .
Both  ||| S:354 E:367 ||| DT
bis-2- ||| S:367 E:373 ||| NNP
( ||| S:373 E:374 ||| -LRB-
chloroethyl ||| S:374 E:385 ||| LS
) ||| S:385 E:386 ||| -RRB-
sulfide ||| S:386 E:393 ||| NN
)  ||| S:393 E:395 ||| -RRB-
and  ||| S:395 E:399 ||| CC
CEES  ||| S:399 E:404 ||| NNP
are  ||| S:404 E:408 ||| VBP
known  ||| S:408 E:414 ||| VBN
to  ||| S:414 E:417 ||| TO
provoke  ||| S:417 E:433 ||| VB
acute  ||| S:433 E:439 ||| JJ
inflammatory  ||| S:439 E:452 ||| JJ
responses  ||| S:452 E:462 ||| NNS
in  ||| S:462 E:465 ||| IN
skin  ||| S:465 E:470 ||| NN
[  ||| S:470 E:472 ||| -LRB-
1  ||| S:472 E:474 ||| CD
2  ||| S:474 E:476 ||| CD
3  ||| S:476 E:478 ||| CD
]  ||| S:478 E:480 ||| -RRB-
.  ||| S:480 E:482 ||| .
The  ||| S:482 E:494 ||| DT
resulting  ||| S:494 E:504 ||| JJ
skin  ||| S:504 E:509 ||| NN
blistering  ||| S:509 E:520 ||| NN
is  ||| S:520 E:523 ||| VBZ
thought  ||| S:523 E:531 ||| VBN
to  ||| S:531 E:534 ||| TO
involve  ||| S:534 E:542 ||| VB
the  ||| S:542 E:554 ||| DT
stimulation  ||| S:554 E:566 ||| NN
of  ||| S:566 E:569 ||| IN
specific  ||| S:569 E:578 ||| JJ
protease ||| S:578 E:586 ||| NNS
( ||| S:586 E:587 ||| -LRB-
s ||| S:587 E:588 ||| LS
)  ||| S:588 E:590 ||| -RRB-
[  ||| S:590 E:592 ||| -LRB-
4  ||| S:592 E:594 ||| LS
]  ||| S:594 E:596 ||| -RRB-
.  ||| S:596 E:598 ||| .
Apoptosis  ||| S:598 E:608 ||| NNP
is  ||| S:608 E:619 ||| VBZ
now  ||| S:619 E:623 ||| RB
considered  ||| S:623 E:634 ||| VBN
a  ||| S:634 E:636 ||| DT
possible  ||| S:636 E:645 ||| JJ
molecular  ||| S:645 E:655 ||| FW
mechanism  ||| S:655 E:665 ||| FW
whereby  ||| S:665 E:673 ||| FW
CEES  ||| S:673 E:686 ||| FW
induces  ||| S:686 E:694 ||| FW
cytotoxicity  ||| S:694 E:707 ||| FW
[  ||| S:707 E:709 ||| -LRB-
5  ||| S:709 E:711 ||| CD
6  ||| S:711 E:713 ||| CD
]  ||| S:713 E:715 ||| -RRB-
.  ||| S:715 E:725 ||| .
LPS  ||| S:725 E:729 ||| NNP
is  ||| S:729 E:732 ||| VBZ
a  ||| S:732 E:734 ||| DT
major  ||| S:734 E:740 ||| JJ
component  ||| S:740 E:750 ||| NN
of  ||| S:750 E:753 ||| IN
the  ||| S:753 E:757 ||| DT
cell  ||| S:757 E:762 ||| NN
wall  ||| S:762 E:767 ||| NN
of  ||| S:767 E:778 ||| IN
gram-negative  ||| S:778 E:792 ||| JJ
bacteria  ||| S:792 E:801 ||| NNS
and  ||| S:801 E:805 ||| CC
is  ||| S:805 E:808 ||| VBZ
known  ||| S:808 E:814 ||| VBN
to  ||| S:814 E:817 ||| TO
trigger  ||| S:817 E:825 ||| VB
a  ||| S:825 E:827 ||| DT
variety  ||| S:827 E:835 ||| NN
of  ||| S:835 E:846 ||| IN
inflammatory  ||| S:846 E:859 ||| JJ
reactions  ||| S:859 E:869 ||| NNS
in  ||| S:869 E:872 ||| IN
macrophages  ||| S:872 E:884 ||| NN
and  ||| S:884 E:888 ||| CC
other  ||| S:888 E:894 ||| JJ
cells  ||| S:894 E:908 ||| NNS
having  ||| S:908 E:915 ||| VBG
CD14  ||| S:915 E:920 ||| CD
receptors  ||| S:920 E:930 ||| NNS
[  ||| S:930 E:932 ||| -LRB-
7  ||| S:932 E:934 ||| CD
8  ||| S:934 E:936 ||| CD
]  ||| S:936 E:938 ||| -RRB-
.  ||| S:938 E:940 ||| .
In  ||| S:940 E:943 ||| IN
particular ||| S:943 E:953 ||| JJ
,  ||| S:953 E:955 ||| ,
LPS  ||| S:955 E:959 ||| NNP
is  ||| S:959 E:962 ||| VBZ
known  ||| S:962 E:976 ||| VBN
to  ||| S:976 E:979 ||| TO
stimulate  ||| S:979 E:989 ||| VB
the  ||| S:989 E:993 ||| DT
macrophage  ||| S:993 E:1004 ||| JJ
secretion  ||| S:1004 E:1014 ||| NN
of  ||| S:1014 E:1017 ||| IN
nitric  ||| S:1017 E:1024 ||| JJ
oxide  ||| S:1024 E:1030 ||| NN
[  ||| S:1030 E:1032 ||| -LRB-
9  ||| S:1032 E:1034 ||| CD
]  ||| S:1034 E:1044 ||| -RRB-
and  ||| S:1044 E:1048 ||| CC
inflammatory  ||| S:1048 E:1061 ||| JJ
cytokines  ||| S:1061 E:1071 ||| JJ
such  ||| S:1071 E:1076 ||| JJ
as  ||| S:1076 E:1079 ||| IN
tumor  ||| S:1079 E:1085 ||| FW
necrosis  ||| S:1085 E:1102 ||| FW
factor-alpha  ||| S:1102 E:1115 ||| FW
( ||| S:1115 E:1116 ||| -LRB-
TNF-alpha ||| S:1116 E:1125 ||| NNP
)  ||| S:1125 E:1127 ||| -RRB-
and  ||| S:1127 E:1131 ||| CC
interleukin-1-beta  ||| S:1131 E:1150 ||| NNP
( ||| S:1150 E:1151 ||| -LRB-
IL-1-beta ||| S:1151 E:1160 ||| NNP
)  ||| S:1160 E:1170 ||| -RRB-
[  ||| S:1170 E:1172 ||| -LRB-
10  ||| S:1172 E:1175 ||| CD
]  ||| S:1175 E:1177 ||| -RRB-
.  ||| S:1177 E:1179 ||| .
For  ||| S:1179 E:1183 ||| IN
this  ||| S:1183 E:1188 ||| DT
reason ||| S:1188 E:1194 ||| NN
,  ||| S:1194 E:1196 ||| ,
we  ||| S:1196 E:1199 ||| PRP
also  ||| S:1199 E:1204 ||| RB
determined  ||| S:1204 E:1215 ||| VBN
if  ||| S:1215 E:1218 ||| IN
TNF-alpha  ||| S:1218 E:1236 ||| JJ
or  ||| S:1236 E:1239 ||| CC
IL-1-beta  ||| S:1239 E:1249 ||| NNP
were  ||| S:1249 E:1254 ||| VBD
capable  ||| S:1254 E:1262 ||| JJ
of  ||| S:1262 E:1265 ||| IN
enhancing  ||| S:1265 E:1275 ||| VBG
the  ||| S:1275 E:1279 ||| DT
cytotoxic  ||| S:1279 E:1297 ||| JJ
effects  ||| S:1297 E:1305 ||| NNS
of  ||| S:1305 E:1308 ||| IN
CEES ||| S:1308 E:1312 ||| NNP
.  ||| S:1312 E:1322 ||| .
LPS  ||| S:1322 E:1326 ||| NNP
stimulation  ||| S:1326 E:1338 ||| NN
of  ||| S:1338 E:1341 ||| IN
macrophages  ||| S:1341 E:1353 ||| NN
is  ||| S:1353 E:1356 ||| VBZ
known  ||| S:1356 E:1362 ||| VBN
to  ||| S:1362 E:1365 ||| TO
involve  ||| S:1365 E:1373 ||| VB
the  ||| S:1373 E:1385 ||| DT
activation  ||| S:1385 E:1396 ||| NN
of  ||| S:1396 E:1399 ||| IN
protein  ||| S:1399 E:1407 ||| NN
phosphorylation  ||| S:1407 E:1423 ||| NN
by  ||| S:1423 E:1426 ||| IN
kinases  ||| S:1426 E:1434 ||| NN
as  ||| S:1434 E:1437 ||| IN
well  ||| S:1437 E:1442 ||| RB
as  ||| S:1442 E:1453 ||| IN
the  ||| S:1453 E:1457 ||| DT
activation  ||| S:1457 E:1468 ||| NN
of  ||| S:1468 E:1471 ||| IN
nuclear  ||| S:1471 E:1479 ||| JJ
transcription  ||| S:1479 E:1493 ||| JJ
factors  ||| S:1493 E:1501 ||| NNS
such  ||| S:1501 E:1506 ||| JJ
as  ||| S:1506 E:1517 ||| IN
NF-kappaB  ||| S:1517 E:1527 ||| NNP
[  ||| S:1527 E:1529 ||| -LRB-
10  ||| S:1529 E:1532 ||| CD
11  ||| S:1532 E:1535 ||| CD
12  ||| S:1535 E:1538 ||| CD
13  ||| S:1538 E:1541 ||| CD
]  ||| S:1541 E:1543 ||| -RRB-
.  ||| S:1543 E:1545 ||| .
The  ||| S:1545 E:1549 ||| DT
activation  ||| S:1549 E:1560 ||| NN
of  ||| S:1560 E:1563 ||| IN
protein  ||| S:1563 E:1579 ||| NN
kinase  ||| S:1579 E:1586 ||| VBD
C  ||| S:1586 E:1588 ||| NNP
( ||| S:1588 E:1589 ||| -LRB-
PKC ||| S:1589 E:1592 ||| NNP
)  ||| S:1592 E:1594 ||| -RRB-
by  ||| S:1594 E:1597 ||| IN
diacylglycerol  ||| S:1597 E:1612 ||| NN
is  ||| S:1612 E:1615 ||| VBZ
also  ||| S:1615 E:1620 ||| RB
a  ||| S:1620 E:1622 ||| DT
key  ||| S:1622 E:1626 ||| JJ
event  ||| S:1626 E:1632 ||| NN
in  ||| S:1632 E:1635 ||| IN
LPS  ||| S:1635 E:1647 ||| NNP
macrophage  ||| S:1647 E:1658 ||| FW
activation  ||| S:1658 E:1669 ||| FW
[  ||| S:1669 E:1671 ||| -LRB-
8  ||| S:1671 E:1673 ||| CD
]  ||| S:1673 E:1675 ||| -RRB-
.  ||| S:1675 E:1686 ||| .
In  ||| S:1686 E:1689 ||| IN
vitro  ||| S:1689 E:1695 ||| JJ
experiments  ||| S:1695 E:1707 ||| NNS
have  ||| S:1707 E:1712 ||| VBP
shown  ||| S:1712 E:1718 ||| VBN
that  ||| S:1718 E:1731 ||| IN
the  ||| S:1731 E:1735 ||| DT
secretion  ||| S:1735 E:1745 ||| NN
of  ||| S:1745 E:1748 ||| IN
TNF-alpha  ||| S:1748 E:1758 ||| JJ
and  ||| S:1758 E:1762 ||| CC
IL-1-beta  ||| S:1762 E:1772 ||| CD
by  ||| S:1772 E:1775 ||| IN
LPS-stimulated  ||| S:1775 E:1798 ||| JJ
monocytes  ||| S:1798 E:1808 ||| NN
is  ||| S:1808 E:1811 ||| VBZ
dependent  ||| S:1811 E:1821 ||| JJ
upon  ||| S:1821 E:1826 ||| IN
PKC  ||| S:1826 E:1830 ||| NNP
activation  ||| S:1830 E:1841 ||| NNS
[  ||| S:1841 E:1843 ||| -LRB-
13  ||| S:1843 E:1846 ||| CD
14  ||| S:1846 E:1849 ||| CD
]  ||| S:1849 E:1851 ||| -RRB-
.  ||| S:1851 E:1853 ||| .
In  ||| S:1853 E:1864 ||| IN
this  ||| S:1864 E:1869 ||| DT
study ||| S:1869 E:1874 ||| NN
,  ||| S:1874 E:1876 ||| ,
we  ||| S:1876 E:1879 ||| PRP
also  ||| S:1879 E:1884 ||| RB
determined  ||| S:1884 E:1895 ||| VBN
if  ||| S:1895 E:1898 ||| IN
phorbol  ||| S:1898 E:1906 ||| FW
myristate  ||| S:1906 E:1916 ||| FW
acetate  ||| S:1916 E:1932 ||| FW
( ||| S:1932 E:1933 ||| -LRB-
PMA ||| S:1933 E:1936 ||| NNP
)  ||| S:1936 E:1938 ||| -RRB-
activation  ||| S:1938 E:1949 ||| NN
of  ||| S:1949 E:1952 ||| IN
PKC  ||| S:1952 E:1956 ||| NNP
also  ||| S:1956 E:1961 ||| RB
enhanced  ||| S:1961 E:1970 ||| VBN
CEES  ||| S:1970 E:1975 ||| NNP
toxicity ||| S:1975 E:1983 ||| NN
.  ||| S:1983 E:1993 ||| .
Evidence  ||| S:1993 E:2002 ||| NN
suggests  ||| S:2002 E:2011 ||| VBZ
that  ||| S:2011 E:2016 ||| IN
LPS  ||| S:2016 E:2020 ||| NNP
[  ||| S:2020 E:2022 ||| -LRB-
15  ||| S:2022 E:2025 ||| CD
16  ||| S:2025 E:2028 ||| CD
]  ||| S:2028 E:2030 ||| -RRB-
as  ||| S:2030 E:2033 ||| IN
well  ||| S:2033 E:2038 ||| RB
as  ||| S:2038 E:2041 ||| IN
TNF-alpha  ||| S:2041 E:2051 ||| NNP
[  ||| S:2051 E:2061 ||| -LRB-
17  ||| S:2061 E:2064 ||| CD
]  ||| S:2064 E:2066 ||| -RRB-
stimulate  ||| S:2066 E:2076 ||| VB
the  ||| S:2076 E:2080 ||| DT
production  ||| S:2080 E:2091 ||| NN
of  ||| S:2091 E:2094 ||| IN
free  ||| S:2094 E:2099 ||| JJ
radicals  ||| S:2099 E:2108 ||| NNS
by  ||| S:2108 E:2119 ||| IN
macrophages ||| S:2119 E:2130 ||| NN
.  ||| S:2130 E:2132 ||| .
Our  ||| S:2132 E:2136 ||| PRP$
long-term  ||| S:2136 E:2146 ||| JJ
goal  ||| S:2146 E:2151 ||| NN
is  ||| S:2151 E:2154 ||| VBZ
to  ||| S:2154 E:2157 ||| TO
understand  ||| S:2157 E:2168 ||| VB
the  ||| S:2168 E:2180 ||| DT
molecular  ||| S:2180 E:2190 ||| JJ
mechanism  ||| S:2190 E:2200 ||| NN
of  ||| S:2200 E:2203 ||| IN
sulfur  ||| S:2203 E:2210 ||| JJ
mustard  ||| S:2210 E:2218 ||| NN
toxicity  ||| S:2218 E:2227 ||| NN
and  ||| S:2227 E:2231 ||| CC
to  ||| S:2231 E:2242 ||| TO
determine  ||| S:2242 E:2252 ||| VB
if  ||| S:2252 E:2255 ||| IN
free  ||| S:2255 E:2260 ||| JJ
radical  ||| S:2260 E:2268 ||| JJ
production  ||| S:2268 E:2279 ||| NN
plays  ||| S:2279 E:2285 ||| VBZ
an  ||| S:2285 E:2288 ||| DT
important  ||| S:2288 E:2306 ||| JJ
role  ||| S:2306 E:2311 ||| NN
in  ||| S:2311 E:2314 ||| IN
this  ||| S:2314 E:2319 ||| DT
toxicity ||| S:2319 E:2327 ||| NN
.  ||| S:2327 E:2337 ||| .
In  ||| S:2337 E:2340 ||| IN
our  ||| S:2340 E:2344 ||| PRP$
experiments ||| S:2344 E:2355 ||| NNS
,  ||| S:2355 E:2357 ||| ,
cytotoxicity  ||| S:2357 E:2370 ||| NN
was  ||| S:2370 E:2374 ||| VBD
measured  ||| S:2374 E:2383 ||| VBN
by  ||| S:2383 E:2386 ||| IN
a  ||| S:2386 E:2396 ||| DT
decrease  ||| S:2396 E:2405 ||| NN
in  ||| S:2405 E:2408 ||| IN
the  ||| S:2408 E:2412 ||| DT
optical  ||| S:2412 E:2420 ||| JJ
density  ||| S:2420 E:2428 ||| NN
by  ||| S:2428 E:2431 ||| IN
the  ||| S:2431 E:2435 ||| DT
MTT  ||| S:2435 E:2447 ||| NNP
( ||| S:2447 E:2448 ||| -LRB-
( ||| S:2448 E:2449 ||| -LRB-
3- ||| S:2449 E:2451 ||| NNP
( ||| S:2451 E:2452 ||| -LRB-
4,5-dimethylthiazol-2-yl ||| S:2452 E:2476 ||| NNP
) ||| S:2476 E:2477 ||| -RRB-
-2,5-diphenyltetrazolium  ||| S:2477 E:2510 ||| FW
bromide ||| S:2510 E:2517 ||| FW
)  ||| S:2517 E:2519 ||| -RRB-
assay  ||| S:2519 E:2525 ||| NN
or  ||| S:2525 E:2528 ||| CC
by  ||| S:2528 E:2531 ||| IN
an  ||| S:2531 E:2534 ||| DT
increase  ||| S:2534 E:2543 ||| NN
in  ||| S:2543 E:2546 ||| IN
the  ||| S:2546 E:2550 ||| DT
fluorescence  ||| S:2550 E:2563 ||| NN
of  ||| S:2563 E:2574 ||| IN
propidium  ||| S:2574 E:2584 ||| JJ
iodide  ||| S:2584 E:2591 ||| NNS
( ||| S:2591 E:2592 ||| -LRB-
PI ||| S:2592 E:2594 ||| NNP
) ||| S:2594 E:2595 ||| -RRB-
.  ||| S:2595 E:2597 ||| .
The  ||| S:2597 E:2601 ||| DT
MTT  ||| S:2601 E:2605 ||| NNP
assay  ||| S:2605 E:2611 ||| NN
is  ||| S:2611 E:2614 ||| VBZ
based  ||| S:2614 E:2620 ||| VBN
on  ||| S:2620 E:2623 ||| IN
reduction  ||| S:2623 E:2641 ||| NN
of  ||| S:2641 E:2644 ||| IN
MTT  ||| S:2644 E:2648 ||| NNP
by  ||| S:2648 E:2651 ||| IN
actively  ||| S:2651 E:2660 ||| RB
growing  ||| S:2660 E:2668 ||| VBG
cells  ||| S:2668 E:2674 ||| NNS
to  ||| S:2674 E:2677 ||| TO
produce  ||| S:2677 E:2685 ||| VB
a  ||| S:2685 E:2687 ||| DT
blue  ||| S:2687 E:2692 ||| JJ
formazan  ||| S:2692 E:2709 ||| JJ
product  ||| S:2709 E:2717 ||| NN
with  ||| S:2717 E:2722 ||| IN
absorbance  ||| S:2722 E:2733 ||| NN
at  ||| S:2733 E:2736 ||| IN
575  ||| S:2736 E:2740 ||| CD
nm ||| S:2740 E:2742 ||| NNS
.  ||| S:2742 E:2744 ||| .
A  ||| S:2744 E:2746 ||| DT
low  ||| S:2746 E:2750 ||| JJ
MTT  ||| S:2750 E:2754 ||| NNP
absorbance  ||| S:2754 E:2773 ||| NN
indicates  ||| S:2773 E:2783 ||| VBZ
cell  ||| S:2783 E:2788 ||| NN
death ||| S:2788 E:2793 ||| NN
.  ||| S:2793 E:2795 ||| .
The  ||| S:2795 E:2799 ||| DT
PI  ||| S:2799 E:2802 ||| NNP
assay  ||| S:2802 E:2808 ||| VBD
differentiates  ||| S:2808 E:2823 ||| VBN
between  ||| S:2823 E:2839 ||| IN
live  ||| S:2839 E:2844 ||| JJ
and  ||| S:2844 E:2848 ||| CC
dead  ||| S:2848 E:2853 ||| JJ
cells ||| S:2853 E:2858 ||| NNS
.  ||| S:2858 E:2860 ||| .
Cells  ||| S:2860 E:2866 ||| NNS
that  ||| S:2866 E:2871 ||| WDT
have  ||| S:2871 E:2876 ||| VBP
lost  ||| S:2876 E:2881 ||| VBN
membrane  ||| S:2881 E:2898 ||| JJ
integrity  ||| S:2898 E:2908 ||| NN
cannot  ||| S:2908 E:2915 ||| NNS
exclude  ||| S:2915 E:2923 ||| VBP
PI ||| S:2923 E:2925 ||| NNP
,  ||| S:2925 E:2927 ||| ,
which  ||| S:2927 E:2933 ||| WDT
emits  ||| S:2933 E:2939 ||| VBZ
a  ||| S:2939 E:2941 ||| DT
red  ||| S:2941 E:2945 ||| JJ
fluorescence  ||| S:2945 E:2966 ||| NN
after  ||| S:2966 E:2972 ||| IN
binding  ||| S:2972 E:2980 ||| VBG
to  ||| S:2980 E:2983 ||| TO
cellular  ||| S:2983 E:2992 ||| JJ
DNA  ||| S:2992 E:2996 ||| NN
or  ||| S:2996 E:2999 ||| CC
double  ||| S:2999 E:3006 ||| RB
stranded  ||| S:3006 E:3015 ||| VBN
RNA ||| S:3015 E:3018 ||| NNP
.  ||| S:3018 E:3020 ||| .
A  ||| S:3020 E:3030 ||| DT
high  ||| S:3030 E:3035 ||| JJ
PI ||| S:3035 E:3037 ||| NNP
%  ||| S:3037 E:3039 ||| NN
indicates  ||| S:3039 E:3049 ||| VBZ
cell  ||| S:3049 E:3054 ||| NN
death ||| S:3054 E:3059 ||| NN
.  ||| S:3059 E:3083 ||| .
Results  ||| S:3083 E:3110 ||| NNS
Cytotoxic  ||| S:3110 E:3120 ||| JJ
interaction  ||| S:3120 E:3132 ||| NN
between  ||| S:3132 E:3140 ||| IN
LPS  ||| S:3140 E:3144 ||| NNP
and  ||| S:3144 E:3148 ||| CC
CEES  ||| S:3148 E:3153 ||| NNP
as  ||| S:3153 E:3166 ||| RB
measured  ||| S:3166 E:3175 ||| VBN
by  ||| S:3175 E:3178 ||| IN
the  ||| S:3178 E:3182 ||| DT
MTT  ||| S:3182 E:3186 ||| NNP
assay  ||| S:3186 E:3202 ||| VBD
RAW  ||| S:3202 E:3206 ||| NNP
264.7  ||| S:3206 E:3212 ||| NNP
macrophages  ||| S:3212 E:3224 ||| NN
were  ||| S:3224 E:3229 ||| VBD
incubated  ||| S:3229 E:3239 ||| VBN
with  ||| S:3239 E:3244 ||| IN
LPS  ||| S:3244 E:3248 ||| NNP
( ||| S:3248 E:3249 ||| -LRB-
100  ||| S:3249 E:3263 ||| CD
ng ||| S:3263 E:3265 ||| CD
/ ||| S:3265 E:3266 ||| CD
ml ||| S:3266 E:3268 ||| CD
) ||| S:3268 E:3269 ||| -RRB-
,  ||| S:3269 E:3271 ||| ,
CEES  ||| S:3271 E:3276 ||| NNP
( ||| S:3276 E:3277 ||| -LRB-
500  ||| S:3277 E:3281 ||| CD
μM ||| S:3281 E:3283 ||| NN
)  ||| S:3283 E:3285 ||| -RRB-
or  ||| S:3285 E:3288 ||| CC
both  ||| S:3288 E:3293 ||| DT
agents  ||| S:3293 E:3300 ||| NNS
for  ||| S:3300 E:3304 ||| IN
24  ||| S:3304 E:3307 ||| CD
hours  ||| S:3307 E:3313 ||| NNS
and  ||| S:3313 E:3327 ||| CC
cell  ||| S:3327 E:3332 ||| NN
viability  ||| S:3332 E:3342 ||| NN
then  ||| S:3342 E:3347 ||| RB
measured  ||| S:3347 E:3356 ||| VBN
by  ||| S:3356 E:3359 ||| IN
the  ||| S:3359 E:3363 ||| DT
MTT  ||| S:3363 E:3367 ||| NNP
assay ||| S:3367 E:3372 ||| NN
.  ||| S:3372 E:3374 ||| .
As  ||| S:3374 E:3377 ||| RB
shown  ||| S:3377 E:3393 ||| VBN
in  ||| S:3393 E:3396 ||| IN
Figure  ||| S:3396 E:3403 ||| NNP
1 ||| S:3403 E:3404 ||| CD
,  ||| S:3404 E:3406 ||| ,
we  ||| S:3406 E:3409 ||| PRP
found  ||| S:3409 E:3415 ||| VBD
that  ||| S:3415 E:3420 ||| DT
LPS-stimulated  ||| S:3420 E:3435 ||| JJ
RAW264.7  ||| S:3435 E:3454 ||| CD
macrophages  ||| S:3454 E:3466 ||| NNS
were  ||| S:3466 E:3471 ||| VBD
markedly  ||| S:3471 E:3480 ||| RB
more  ||| S:3480 E:3485 ||| RBR
susceptible  ||| S:3485 E:3497 ||| JJ
( ||| S:3497 E:3498 ||| -LRB-
p  ||| S:3498 E:3500 ||| CD
< ||| S:3500 E:3502 ||| SYM
0.05 ||| S:3502 E:3506 ||| CD
)  ||| S:3506 E:3518 ||| -RRB-
to  ||| S:3518 E:3521 ||| TO
CEES  ||| S:3521 E:3526 ||| NNP
toxicity  ||| S:3526 E:3535 ||| NNS
( ||| S:3535 E:3536 ||| -LRB-
24  ||| S:3536 E:3539 ||| CD
hr ||| S:3539 E:3541 ||| CD
)  ||| S:3541 E:3543 ||| -RRB-
than  ||| S:3543 E:3548 ||| IN
resting  ||| S:3548 E:3556 ||| JJ
macrophages  ||| S:3556 E:3568 ||| NN
as  ||| S:3568 E:3581 ||| IN
indicated  ||| S:3581 E:3591 ||| VBN
by  ||| S:3591 E:3594 ||| IN
the  ||| S:3594 E:3598 ||| DT
dramatic  ||| S:3598 E:3607 ||| JJ
drop  ||| S:3607 E:3612 ||| NN
in  ||| S:3612 E:3615 ||| IN
dehydrogenase  ||| S:3615 E:3629 ||| JJ
activity ||| S:3629 E:3637 ||| NN
.  ||| S:3637 E:3649 ||| .
In  ||| S:3649 E:3652 ||| IN
the  ||| S:3652 E:3656 ||| DT
absence  ||| S:3656 E:3664 ||| NN
of  ||| S:3664 E:3667 ||| IN
LPS ||| S:3667 E:3670 ||| NNP
,  ||| S:3670 E:3672 ||| ,
CEES  ||| S:3672 E:3677 ||| NNP
at  ||| S:3677 E:3680 ||| IN
a  ||| S:3680 E:3682 ||| DT
level  ||| S:3682 E:3688 ||| NN
of  ||| S:3688 E:3691 ||| IN
500  ||| S:3691 E:3695 ||| CD
μM  ||| S:3695 E:3698 ||| NN
did  ||| S:3698 E:3702 ||| VBD
not  ||| S:3702 E:3716 ||| RB
significantly  ||| S:3716 E:3730 ||| RB
affect  ||| S:3730 E:3737 ||| VB
cell  ||| S:3737 E:3742 ||| NN
viability  ||| S:3742 E:3752 ||| NN
as  ||| S:3752 E:3755 ||| IN
measured  ||| S:3755 E:3764 ||| VBN
by  ||| S:3764 E:3767 ||| IN
the  ||| S:3767 E:3781 ||| DT
MTT  ||| S:3781 E:3785 ||| NNP
assay ||| S:3785 E:3790 ||| NN
.  ||| S:3790 E:3802 ||| .
The  ||| S:3802 E:3806 ||| DT
characteristics  ||| S:3806 E:3822 ||| NN
of  ||| S:3822 E:3825 ||| IN
CEES  ||| S:3825 E:3830 ||| NNP
toxicity  ||| S:3830 E:3839 ||| VBD
to  ||| S:3839 E:3842 ||| TO
LPS-stimulated  ||| S:3842 E:3867 ||| NNP
RAW  ||| S:3867 E:3871 ||| NNP
264.7  ||| S:3871 E:3877 ||| NNP
macrophages  ||| S:3877 E:3889 ||| NN
were  ||| S:3889 E:3894 ||| VBD
further  ||| S:3894 E:3902 ||| RB
characterized  ||| S:3902 E:3916 ||| VBN
by  ||| S:3916 E:3929 ||| IN
varying  ||| S:3929 E:3937 ||| VBG
the  ||| S:3937 E:3941 ||| DT
concentrations  ||| S:3941 E:3956 ||| NNS
of  ||| S:3956 E:3959 ||| IN
both  ||| S:3959 E:3964 ||| DT
LPS  ||| S:3964 E:3968 ||| NNP
and  ||| S:3968 E:3972 ||| CC
CEES ||| S:3972 E:3976 ||| NNP
.  ||| S:3976 E:3978 ||| .
The  ||| S:3978 E:3982 ||| DT
MTT  ||| S:3982 E:3996 ||| NNP
data  ||| S:3996 E:4001 ||| NNS
in  ||| S:4001 E:4004 ||| IN
Figure  ||| S:4004 E:4011 ||| NNP
2show  ||| S:4011 E:4017 ||| NNP
that  ||| S:4017 E:4022 ||| IN
very  ||| S:4022 E:4027 ||| RB
low  ||| S:4027 E:4031 ||| JJ
levels  ||| S:4031 E:4038 ||| NNS
( ||| S:4038 E:4039 ||| -LRB-
25  ||| S:4039 E:4042 ||| CD
ng ||| S:4042 E:4044 ||| CD
/ ||| S:4044 E:4045 ||| CD
ml ||| S:4045 E:4047 ||| CD
)  ||| S:4047 E:4049 ||| -RRB-
of  ||| S:4049 E:4062 ||| IN
LPS  ||| S:4062 E:4066 ||| NNP
dramatically  ||| S:4066 E:4079 ||| RB
enhanced  ||| S:4079 E:4088 ||| VBN
the  ||| S:4088 E:4092 ||| DT
toxicity  ||| S:4092 E:4101 ||| NN
of  ||| S:4101 E:4104 ||| IN
CEES  ||| S:4104 E:4109 ||| NNP
( ||| S:4109 E:4110 ||| -LRB-
measured  ||| S:4110 E:4129 ||| VBN
after  ||| S:4129 E:4135 ||| IN
24  ||| S:4135 E:4138 ||| CD
hr ||| S:4138 E:4140 ||| CD
)  ||| S:4140 E:4142 ||| -RRB-
to  ||| S:4142 E:4145 ||| TO
macrophages  ||| S:4145 E:4157 ||| VB
at  ||| S:4157 E:4160 ||| IN
concentrations  ||| S:4160 E:4175 ||| CD
>  ||| S:4175 E:4177 ||| CD
300  ||| S:4177 E:4191 ||| CD
μM ||| S:4191 E:4193 ||| NN
.  ||| S:4193 E:4195 ||| .
In  ||| S:4195 E:4198 ||| IN
general ||| S:4198 E:4205 ||| JJ
,  ||| S:4205 E:4207 ||| ,
LPS  ||| S:4207 E:4211 ||| NNP
levels  ||| S:4211 E:4218 ||| NNS
beyond  ||| S:4218 E:4225 ||| IN
25  ||| S:4225 E:4228 ||| CD
ng ||| S:4228 E:4230 ||| CD
/ ||| S:4230 E:4231 ||| CD
ml  ||| S:4231 E:4234 ||| NNS
did  ||| S:4234 E:4238 ||| VBD
not  ||| S:4238 E:4252 ||| RB
further  ||| S:4252 E:4260 ||| RB
enhance  ||| S:4260 E:4268 ||| VB
the  ||| S:4268 E:4272 ||| DT
toxicity  ||| S:4272 E:4281 ||| NN
of  ||| S:4281 E:4284 ||| IN
CEES ||| S:4284 E:4288 ||| NNP
.  ||| S:4288 E:4290 ||| .
However ||| S:4290 E:4297 ||| RB
,  ||| S:4297 E:4299 ||| ,
LPS  ||| S:4299 E:4303 ||| NNP
level  ||| S:4303 E:4319 ||| NN
at  ||| S:4319 E:4322 ||| IN
a  ||| S:4322 E:4324 ||| DT
level  ||| S:4324 E:4330 ||| NN
of  ||| S:4330 E:4333 ||| IN
100  ||| S:4333 E:4337 ||| CD
ng ||| S:4337 E:4339 ||| CD
/ ||| S:4339 E:4340 ||| CD
ml  ||| S:4340 E:4343 ||| NNS
significantly  ||| S:4343 E:4357 ||| RB
increased  ||| S:4357 E:4367 ||| VBD
the  ||| S:4367 E:4381 ||| DT
cytotoxicity  ||| S:4381 E:4394 ||| NN
of  ||| S:4394 E:4397 ||| IN
300  ||| S:4397 E:4401 ||| CD
μM  ||| S:4401 E:4404 ||| JJ
CEES  ||| S:4404 E:4409 ||| NNS
compared  ||| S:4409 E:4418 ||| VBN
to  ||| S:4418 E:4421 ||| TO
LPS  ||| S:4421 E:4425 ||| NNP
activated  ||| S:4425 E:4445 ||| VBD
RAW265.7  ||| S:4445 E:4454 ||| CD
cells  ||| S:4454 E:4460 ||| NNS
not  ||| S:4460 E:4464 ||| RB
treated  ||| S:4464 E:4472 ||| VBN
with  ||| S:4472 E:4477 ||| IN
CEES ||| S:4477 E:4481 ||| NNP
.  ||| S:4481 E:4483 ||| .
Statistical  ||| S:4483 E:4505 ||| JJ
analyses  ||| S:4505 E:4514 ||| NNS
indicate  ||| S:4514 E:4523 ||| VBP
that  ||| S:4523 E:4528 ||| IN
cells  ||| S:4528 E:4534 ||| NNS
treated  ||| S:4534 E:4542 ||| VBN
with  ||| S:4542 E:4547 ||| IN
100  ||| S:4547 E:4551 ||| CD
μM  ||| S:4551 E:4554 ||| JJ
CEES  ||| S:4554 E:4569 ||| NNP
were  ||| S:4569 E:4574 ||| VBD
not  ||| S:4574 E:4578 ||| RB
significantly  ||| S:4578 E:4592 ||| RB
different  ||| S:4592 E:4602 ||| JJ
from  ||| S:4602 E:4607 ||| IN
control  ||| S:4607 E:4615 ||| NN
cells  ||| S:4615 E:4621 ||| NNS
( ||| S:4621 E:4622 ||| -LRB-
not  ||| S:4622 E:4636 ||| RB
treated  ||| S:4636 E:4644 ||| VBN
with  ||| S:4644 E:4649 ||| IN
CEES ||| S:4649 E:4653 ||| NNP
)  ||| S:4653 E:4655 ||| -RRB-
in  ||| S:4655 E:4658 ||| IN
the  ||| S:4658 E:4662 ||| DT
presence  ||| S:4662 E:4671 ||| NN
of  ||| S:4671 E:4674 ||| IN
0 ||| S:4674 E:4675 ||| CD
,  ||| S:4675 E:4677 ||| ,
25  ||| S:4677 E:4680 ||| CD
or  ||| S:4680 E:4683 ||| CC
50  ||| S:4683 E:4686 ||| CD
ng ||| S:4686 E:4688 ||| CD
/ ||| S:4688 E:4689 ||| CD
ml  ||| S:4689 E:4702 ||| NN
of  ||| S:4702 E:4705 ||| IN
LPS ||| S:4705 E:4708 ||| NNP
.  ||| S:4708 E:4710 ||| .
However ||| S:4710 E:4717 ||| RB
,  ||| S:4717 E:4719 ||| ,
at  ||| S:4719 E:4722 ||| IN
a  ||| S:4722 E:4724 ||| DT
LPS  ||| S:4724 E:4728 ||| NNP
level  ||| S:4728 E:4734 ||| NN
of  ||| S:4734 E:4737 ||| IN
100  ||| S:4737 E:4741 ||| CD
ng ||| S:4741 E:4743 ||| CD
/ ||| S:4743 E:4744 ||| CD
ml ||| S:4744 E:4746 ||| NN
,  ||| S:4746 E:4748 ||| ,
cells  ||| S:4748 E:4764 ||| NNS
treated  ||| S:4764 E:4772 ||| VBN
with  ||| S:4772 E:4777 ||| IN
100  ||| S:4777 E:4781 ||| CD
μM  ||| S:4781 E:4784 ||| JJ
CEES  ||| S:4784 E:4789 ||| NNP
showed  ||| S:4789 E:4796 ||| VBD
a  ||| S:4796 E:4798 ||| DT
great  ||| S:4798 E:4804 ||| JJ
MTT  ||| S:4804 E:4808 ||| NNP
optical  ||| S:4808 E:4826 ||| JJ
density  ||| S:4826 E:4834 ||| NN
than  ||| S:4834 E:4839 ||| IN
control  ||| S:4839 E:4847 ||| NN
cells ||| S:4847 E:4852 ||| NNS
.  ||| S:4852 E:4854 ||| .
This  ||| S:4854 E:4859 ||| DT
might  ||| S:4859 E:4865 ||| MD
be  ||| S:4865 E:4868 ||| VB
due  ||| S:4868 E:4872 ||| JJ
to  ||| S:4872 E:4875 ||| TO
a  ||| S:4875 E:4877 ||| DT
slight  ||| S:4877 E:4894 ||| JJ
mitogenic  ||| S:4894 E:4904 ||| JJ
response  ||| S:4904 E:4913 ||| NN
to  ||| S:4913 E:4916 ||| TO
low  ||| S:4916 E:4920 ||| JJ
levels  ||| S:4920 E:4927 ||| NNS
of  ||| S:4927 E:4930 ||| IN
CEES ||| S:4930 E:4934 ||| NNP
.  ||| S:4934 E:4964 ||| .
Time  ||| S:4964 E:4969 ||| NN
course  ||| S:4969 E:4976 ||| NN
for  ||| S:4976 E:4980 ||| IN
the  ||| S:4980 E:4984 ||| DT
cytotoxic  ||| S:4984 E:4994 ||| JJ
interaction  ||| S:4994 E:5006 ||| NN
between  ||| S:5006 E:5024 ||| IN
LPS  ||| S:5024 E:5028 ||| NNP
and  ||| S:5028 E:5032 ||| CC
CEES  ||| S:5032 E:5037 ||| NNP
as  ||| S:5037 E:5040 ||| RB
measured  ||| S:5040 E:5049 ||| VBN
by  ||| S:5049 E:5052 ||| IN
the  ||| S:5052 E:5056 ||| DT
propidium  ||| S:5056 E:5066 ||| JJ
iodide  ||| S:5066 E:5073 ||| NNS
( ||| S:5073 E:5074 ||| -LRB-
PI ||| S:5074 E:5076 ||| NNP
)  ||| S:5076 E:5088 ||| -RRB-
assay  ||| S:5088 E:5104 ||| NN
In  ||| S:5104 E:5107 ||| IN
order  ||| S:5107 E:5113 ||| NN
to  ||| S:5113 E:5116 ||| TO
insure  ||| S:5116 E:5123 ||| VB
that  ||| S:5123 E:5128 ||| IN
our  ||| S:5128 E:5132 ||| PRP$
results  ||| S:5132 E:5140 ||| NNS
could  ||| S:5140 E:5146 ||| MD
be  ||| S:5146 E:5159 ||| VB
reproduced  ||| S:5159 E:5170 ||| VBN
with  ||| S:5170 E:5175 ||| IN
an  ||| S:5175 E:5178 ||| DT
alternative  ||| S:5178 E:5190 ||| JJ
assay  ||| S:5190 E:5196 ||| NN
for  ||| S:5196 E:5200 ||| IN
cell  ||| S:5200 E:5205 ||| NN
viability ||| S:5205 E:5214 ||| NN
,  ||| S:5214 E:5226 ||| ,
we  ||| S:5226 E:5229 ||| PRP
also  ||| S:5229 E:5234 ||| RB
utilized  ||| S:5234 E:5243 ||| VB
the  ||| S:5243 E:5247 ||| DT
propidium  ||| S:5247 E:5257 ||| JJ
iodide  ||| S:5257 E:5264 ||| NNS
( ||| S:5264 E:5265 ||| -LRB-
PI ||| S:5265 E:5267 ||| NNP
)  ||| S:5267 E:5269 ||| -RRB-
assay ||| S:5269 E:5274 ||| NN
.  ||| S:5274 E:5276 ||| .
In  ||| S:5276 E:5279 ||| IN
this  ||| S:5279 E:5294 ||| DT
assay ||| S:5294 E:5299 ||| NN
,  ||| S:5299 E:5301 ||| ,
the  ||| S:5301 E:5305 ||| DT
percent  ||| S:5305 E:5313 ||| NN
fluorescence  ||| S:5313 E:5326 ||| NN
increase  ||| S:5326 E:5335 ||| NN
over  ||| S:5335 E:5340 ||| IN
the  ||| S:5340 E:5344 ||| DT
control  ||| S:5344 E:5362 ||| NN
cells  ||| S:5362 E:5368 ||| NNS
( ||| S:5368 E:5369 ||| -LRB-
i.e. ||| S:5369 E:5373 ||| FW
,  ||| S:5373 E:5375 ||| ,
100  ||| S:5375 E:5379 ||| CD
×  ||| S:5379 E:5381 ||| CD
( ||| S:5381 E:5382 ||| -LRB-
PI  ||| S:5382 E:5396 ||| NNP
treatment  ||| S:5396 E:5406 ||| NN
-PI  ||| S:5406 E:5421 ||| JJ
control  ||| S:5421 E:5429 ||| NN
) ||| S:5429 E:5430 ||| -RRB-
/ ||| S:5430 E:5431 ||| NNP
PI  ||| S:5431 E:5445 ||| NNP
control  ||| S:5445 E:5453 ||| NN
)  ||| S:5453 E:5455 ||| -RRB-
indicates  ||| S:5455 E:5465 ||| VBZ
cytotoxicity ||| S:5465 E:5477 ||| VBN
.  ||| S:5477 E:5479 ||| .
For  ||| S:5479 E:5493 ||| IN
each  ||| S:5493 E:5498 ||| DT
experiment ||| S:5498 E:5508 ||| NN
,  ||| S:5508 E:5510 ||| ,
the  ||| S:5510 E:5514 ||| DT
value  ||| S:5514 E:5520 ||| NN
for  ||| S:5520 E:5524 ||| IN
the  ||| S:5524 E:5528 ||| DT
control  ||| S:5528 E:5536 ||| NN
cells  ||| S:5536 E:5542 ||| NNS
is  ||| S:5542 E:5545 ||| VBZ
zero  ||| S:5545 E:5560 ||| CD
and  ||| S:5560 E:5564 ||| CC
is  ||| S:5564 E:5567 ||| VBZ
not ||| S:5567 E:5570 ||| RB
,  ||| S:5570 E:5572 ||| ,
therefore ||| S:5572 E:5581 ||| RB
,  ||| S:5581 E:5583 ||| ,
shown ||| S:5583 E:5588 ||| VBN
.  ||| S:5588 E:5590 ||| .
Figure  ||| S:5590 E:5597 ||| NN
3indicates  ||| S:5597 E:5608 ||| NN
that  ||| S:5608 E:5613 ||| IN
the  ||| S:5613 E:5627 ||| DT
PI  ||| S:5627 E:5630 ||| NNP
assay  ||| S:5630 E:5636 ||| NN
provides  ||| S:5636 E:5645 ||| VBZ
the  ||| S:5645 E:5649 ||| DT
same  ||| S:5649 E:5654 ||| JJ
qualitative  ||| S:5654 E:5666 ||| JJ
results  ||| S:5666 E:5674 ||| NNS
as  ||| S:5674 E:5677 ||| IN
the  ||| S:5677 E:5681 ||| DT
MTT  ||| S:5681 E:5695 ||| NNP
assay ||| S:5695 E:5700 ||| NN
,  ||| S:5700 E:5702 ||| ,
i.e. ||| S:5702 E:5706 ||| FW
,  ||| S:5706 E:5708 ||| ,
a  ||| S:5708 E:5710 ||| DT
synergistic  ||| S:5710 E:5722 ||| JJ
toxic  ||| S:5722 E:5728 ||| JJ
interaction  ||| S:5728 E:5740 ||| NN
between  ||| S:5740 E:5748 ||| IN
CEES  ||| S:5748 E:5763 ||| NNP
( ||| S:5763 E:5764 ||| -LRB-
500  ||| S:5764 E:5768 ||| CD
μM ||| S:5768 E:5770 ||| NN
)  ||| S:5770 E:5772 ||| -RRB-
and  ||| S:5772 E:5776 ||| CC
LPS  ||| S:5776 E:5780 ||| NNP
( ||| S:5780 E:5781 ||| -LRB-
20  ||| S:5781 E:5784 ||| CD
ng ||| S:5784 E:5786 ||| CD
/ ||| S:5786 E:5787 ||| CD
ml ||| S:5787 E:5789 ||| CD
) ||| S:5789 E:5790 ||| -RRB-
.  ||| S:5790 E:5792 ||| .
Moreover ||| S:5792 E:5800 ||| RB
,  ||| S:5800 E:5802 ||| ,
the  ||| S:5802 E:5806 ||| DT
cytotoxic  ||| S:5806 E:5826 ||| JJ
interaction  ||| S:5826 E:5838 ||| NN
between  ||| S:5838 E:5846 ||| IN
LPS  ||| S:5846 E:5850 ||| NNP
and  ||| S:5850 E:5854 ||| CC
CEES  ||| S:5854 E:5859 ||| NNP
was  ||| S:5859 E:5863 ||| VBD
noticeable  ||| S:5863 E:5874 ||| VBN
after  ||| S:5874 E:5880 ||| IN
6  ||| S:5880 E:5892 ||| CD
hours  ||| S:5892 E:5898 ||| NNS
( ||| S:5898 E:5899 ||| -LRB-
p  ||| S:5899 E:5901 ||| CD
< ||| S:5901 E:5903 ||| SYM
0.05 ||| S:5903 E:5907 ||| CD
)  ||| S:5907 E:5909 ||| -RRB-
and  ||| S:5909 E:5913 ||| CC
reached  ||| S:5913 E:5921 ||| VBD
a  ||| S:5921 E:5923 ||| DT
maximum  ||| S:5923 E:5931 ||| JJ
12  ||| S:5931 E:5934 ||| CD
hours  ||| S:5934 E:5940 ||| NNS
after  ||| S:5940 E:5956 ||| IN
exposure ||| S:5956 E:5964 ||| NN
.  ||| S:5964 E:5966 ||| .
After  ||| S:5966 E:5972 ||| IN
24  ||| S:5972 E:5975 ||| CD
hours ||| S:5975 E:5980 ||| NNS
,  ||| S:5980 E:5982 ||| ,
CEES  ||| S:5982 E:5987 ||| NNP
( ||| S:5987 E:5988 ||| -LRB-
500  ||| S:5988 E:5992 ||| CD
μM ||| S:5992 E:5994 ||| NN
)  ||| S:5994 E:5996 ||| -RRB-
was  ||| S:5996 E:6000 ||| VBD
significantly  ||| S:6000 E:6024 ||| RB
toxic  ||| S:6024 E:6030 ||| JJ
to  ||| S:6030 E:6033 ||| TO
RAW  ||| S:6033 E:6037 ||| NNP
264.7  ||| S:6037 E:6043 ||| NNP
macrophages  ||| S:6043 E:6055 ||| VBD
even  ||| S:6055 E:6060 ||| RB
in  ||| S:6060 E:6063 ||| IN
the  ||| S:6063 E:6067 ||| DT
absence  ||| S:6067 E:6075 ||| NN
of  ||| S:6075 E:6088 ||| IN
LPS ||| S:6088 E:6091 ||| NNP
.  ||| S:6091 E:6093 ||| .
LPS  ||| S:6093 E:6097 ||| NNP
alone  ||| S:6097 E:6103 ||| RB
was  ||| S:6103 E:6107 ||| VBD
never  ||| S:6107 E:6113 ||| RB
significantly  ||| S:6113 E:6127 ||| RB
different  ||| S:6127 E:6137 ||| JJ
than  ||| S:6137 E:6152 ||| IN
cells  ||| S:6152 E:6158 ||| NNS
with  ||| S:6158 E:6163 ||| IN
no  ||| S:6163 E:6166 ||| DT
treatment ||| S:6166 E:6175 ||| NN
,  ||| S:6175 E:6177 ||| ,
which  ||| S:6177 E:6183 ||| WDT
always  ||| S:6183 E:6190 ||| RB
has  ||| S:6190 E:6194 ||| VBZ
a  ||| S:6194 E:6196 ||| DT
zero  ||| S:6196 E:6201 ||| CD
percent  ||| S:6201 E:6219 ||| NN
PI ||| S:6219 E:6221 ||| NNP
%  ||| S:6221 E:6223 ||| NN
increase ||| S:6223 E:6231 ||| NN
.  ||| S:6231 E:6261 ||| .
TNF-alpha  ||| S:6261 E:6271 ||| NNP
and  ||| S:6271 E:6275 ||| CC
IL-1beta  ||| S:6275 E:6284 ||| NNP
also  ||| S:6284 E:6289 ||| RB
enhance  ||| S:6289 E:6297 ||| VB
the  ||| S:6297 E:6301 ||| DT
cytotoxic  ||| S:6301 E:6321 ||| JJ
effect  ||| S:6321 E:6328 ||| NN
of  ||| S:6328 E:6331 ||| IN
CEES  ||| S:6331 E:6346 ||| NNP
LPS  ||| S:6346 E:6350 ||| NNP
from  ||| S:6350 E:6355 ||| IN
Gram-negative  ||| S:6355 E:6369 ||| JJ
bacteria  ||| S:6369 E:6378 ||| NNS
binds  ||| S:6378 E:6384 ||| VBP
to  ||| S:6384 E:6387 ||| TO
CD14  ||| S:6387 E:6392 ||| CD
and  ||| S:6392 E:6406 ||| CC
initiates  ||| S:6406 E:6416 ||| VBG
a  ||| S:6416 E:6418 ||| DT
complex  ||| S:6418 E:6426 ||| JJ
signal  ||| S:6426 E:6433 ||| NN
transduction  ||| S:6433 E:6446 ||| NNS
pathway  ||| S:6446 E:6454 ||| VBP
involving  ||| S:6454 E:6474 ||| VBG
the  ||| S:6474 E:6478 ||| DT
Toll  ||| S:6478 E:6483 ||| JJ
receptor  ||| S:6483 E:6492 ||| NN
family ||| S:6492 E:6498 ||| NN
,  ||| S:6498 E:6500 ||| ,
which  ||| S:6500 E:6506 ||| WDT
eventually  ||| S:6506 E:6517 ||| RB
results  ||| S:6517 E:6525 ||| NNS
in  ||| S:6525 E:6528 ||| IN
the  ||| S:6528 E:6542 ||| DT
synthesis  ||| S:6542 E:6552 ||| NN
of  ||| S:6552 E:6555 ||| IN
pro-inflammatory  ||| S:6555 E:6572 ||| JJ
cytokines  ||| S:6572 E:6582 ||| JJ
such  ||| S:6582 E:6587 ||| JJ
as  ||| S:6587 E:6590 ||| IN
TNF-alpha  ||| S:6590 E:6610 ||| JJ
and  ||| S:6610 E:6614 ||| CC
IL-1beta ||| S:6614 E:6622 ||| NNP
.  ||| S:6622 E:6624 ||| .
We ||| S:6624 E:6626 ||| PRP
,  ||| S:6626 E:6628 ||| ,
therefore ||| S:6628 E:6637 ||| RB
,  ||| S:6637 E:6639 ||| ,
investigated  ||| S:6639 E:6652 ||| VBD
the  ||| S:6652 E:6656 ||| DT
potential  ||| S:6656 E:6676 ||| JJ
roles  ||| S:6676 E:6682 ||| NNS
of  ||| S:6682 E:6685 ||| IN
TNF-alpha  ||| S:6685 E:6695 ||| JJ
and  ||| S:6695 E:6699 ||| CC
IL-1beta  ||| S:6699 E:6708 ||| CD
in  ||| S:6708 E:6711 ||| IN
enhancing  ||| S:6711 E:6721 ||| VBG
CEES  ||| S:6721 E:6736 ||| NNP
cytotoxicity ||| S:6736 E:6748 ||| NN
.  ||| S:6748 E:6750 ||| .
Table  ||| S:6750 E:6756 ||| NN
1shows  ||| S:6756 E:6763 ||| NN
that  ||| S:6763 E:6768 ||| IN
IL-1beta  ||| S:6768 E:6777 ||| NNP
( ||| S:6777 E:6778 ||| -LRB-
50  ||| S:6778 E:6781 ||| CD
ng ||| S:6781 E:6783 ||| CD
/ ||| S:6783 E:6784 ||| CD
ml ||| S:6784 E:6786 ||| CD
)  ||| S:6786 E:6788 ||| -RRB-
and  ||| S:6788 E:6802 ||| CC
CEES  ||| S:6802 E:6807 ||| NNP
( ||| S:6807 E:6808 ||| -LRB-
500  ||| S:6808 E:6812 ||| CD
μM ||| S:6812 E:6814 ||| NN
)  ||| S:6814 E:6816 ||| -RRB-
are  ||| S:6816 E:6820 ||| VBP
significantly  ||| S:6820 E:6834 ||| RB
more  ||| S:6834 E:6839 ||| JJR
cytotoxic  ||| S:6839 E:6849 ||| NNS
( ||| S:6849 E:6850 ||| -LRB-
after  ||| S:6850 E:6856 ||| IN
24  ||| S:6856 E:6869 ||| CD
hours ||| S:6869 E:6874 ||| NNS
)  ||| S:6874 E:6876 ||| -RRB-
when  ||| S:6876 E:6881 ||| WRB
administered  ||| S:6881 E:6894 ||| VBN
together  ||| S:6894 E:6903 ||| RP
than  ||| S:6903 E:6908 ||| IN
when  ||| S:6908 E:6913 ||| WRB
administered  ||| S:6913 E:6936 ||| VBN
alone ||| S:6936 E:6941 ||| RB
.  ||| S:6941 E:6943 ||| .
In  ||| S:6943 E:6946 ||| IN
this  ||| S:6946 E:6951 ||| DT
experiment ||| S:6951 E:6961 ||| NN
,  ||| S:6961 E:6963 ||| ,
LPS  ||| S:6963 E:6967 ||| NNP
( ||| S:6967 E:6968 ||| -LRB-
25  ||| S:6968 E:6971 ||| CD
ng ||| S:6971 E:6973 ||| CD
/ ||| S:6973 E:6974 ||| CD
ml ||| S:6974 E:6976 ||| CD
)  ||| S:6976 E:6978 ||| -RRB-
and  ||| S:6978 E:6982 ||| CC
CEES  ||| S:6982 E:6987 ||| NNP
( ||| S:6987 E:6988 ||| -LRB-
500  ||| S:6988 E:7002 ||| CD
μM ||| S:7002 E:7004 ||| NN
)  ||| S:7004 E:7006 ||| -RRB-
combined  ||| S:7006 E:7015 ||| VBN
gave  ||| S:7015 E:7020 ||| VBD
PI ||| S:7020 E:7022 ||| NNP
( ||| S:7022 E:7023 ||| -LRB-
% ||| S:7023 E:7024 ||| NN
)  ||| S:7024 E:7026 ||| -RRB-
and  ||| S:7026 E:7030 ||| CC
MTT  ||| S:7030 E:7034 ||| NNP
values  ||| S:7034 E:7041 ||| NNS
of  ||| S:7041 E:7044 ||| IN
120.8  ||| S:7044 E:7050 ||| CD
±  ||| S:7050 E:7052 ||| CD
2.3  ||| S:7052 E:7056 ||| CD
and  ||| S:7056 E:7070 ||| CC
0.25  ||| S:7070 E:7075 ||| CD
±  ||| S:7075 E:7077 ||| CD
0.07 ||| S:7077 E:7081 ||| CD
,  ||| S:7081 E:7083 ||| ,
respectively ||| S:7083 E:7095 ||| RB
.  ||| S:7095 E:7097 ||| .
These  ||| S:7097 E:7103 ||| DT
MTT  ||| S:7103 E:7107 ||| NNP
data  ||| S:7107 E:7112 ||| NNS
suggest  ||| S:7112 E:7120 ||| VBP
that  ||| S:7120 E:7135 ||| IN
LPS ||| S:7135 E:7138 ||| NNP
,  ||| S:7138 E:7140 ||| ,
at  ||| S:7140 E:7143 ||| IN
25  ||| S:7143 E:7146 ||| CD
ng ||| S:7146 E:7148 ||| CD
/ ||| S:7148 E:7149 ||| CD
ml ||| S:7149 E:7151 ||| NN
,  ||| S:7151 E:7153 ||| ,
is  ||| S:7153 E:7156 ||| VBZ
able  ||| S:7156 E:7161 ||| JJ
to  ||| S:7161 E:7164 ||| TO
enhance  ||| S:7164 E:7172 ||| VB
the  ||| S:7172 E:7176 ||| DT
toxicity  ||| S:7176 E:7185 ||| NN
of  ||| S:7185 E:7188 ||| IN
CEES  ||| S:7188 E:7203 ||| NNP
( ||| S:7203 E:7204 ||| -LRB-
an  ||| S:7204 E:7207 ||| DT
MTT  ||| S:7207 E:7211 ||| NNP
value  ||| S:7211 E:7217 ||| NN
of  ||| S:7217 E:7220 ||| IN
0.25  ||| S:7220 E:7225 ||| CD
±  ||| S:7225 E:7227 ||| CD
0.07 ||| S:7227 E:7231 ||| CD
)  ||| S:7231 E:7233 ||| -RRB-
to  ||| S:7233 E:7236 ||| TO
a  ||| S:7236 E:7238 ||| DT
greater  ||| S:7238 E:7246 ||| JJR
extent  ||| S:7246 E:7253 ||| NN
( ||| S:7253 E:7254 ||| -LRB-
p  ||| S:7254 E:7256 ||| CD
< ||| S:7256 E:7257 ||| SYM
0.05 ||| S:7268 E:7272 ||| CD
)  ||| S:7272 E:7274 ||| -RRB-
than  ||| S:7274 E:7279 ||| IN
IL-1beta  ||| S:7279 E:7288 ||| CD
at  ||| S:7288 E:7291 ||| IN
50  ||| S:7291 E:7294 ||| CD
ng ||| S:7294 E:7296 ||| CD
/ ||| S:7296 E:7297 ||| CD
ml  ||| S:7297 E:7300 ||| NNS
( ||| S:7300 E:7301 ||| -LRB-
an  ||| S:7301 E:7304 ||| DT
MTT  ||| S:7304 E:7308 ||| NNP
value  ||| S:7308 E:7314 ||| NN
of  ||| S:7314 E:7317 ||| IN
0.74  ||| S:7317 E:7322 ||| CD
±  ||| S:7322 E:7334 ||| CD
0.07 ||| S:7334 E:7338 ||| CD
) ||| S:7338 E:7339 ||| -RRB-
.  ||| S:7339 E:7341 ||| .
The  ||| S:7341 E:7345 ||| DT
ternary  ||| S:7345 E:7353 ||| JJ
mixture  ||| S:7353 E:7361 ||| NN
of  ||| S:7361 E:7364 ||| IN
LPS  ||| S:7364 E:7368 ||| NNP
( ||| S:7368 E:7369 ||| -LRB-
25  ||| S:7369 E:7372 ||| CD
ng ||| S:7372 E:7374 ||| CD
/ ||| S:7374 E:7375 ||| CD
ml ||| S:7375 E:7377 ||| CD
) ||| S:7377 E:7378 ||| -RRB-
,  ||| S:7378 E:7380 ||| ,
IL-1beta  ||| S:7380 E:7399 ||| NNP
( ||| S:7399 E:7400 ||| -LRB-
50  ||| S:7400 E:7403 ||| CD
ng ||| S:7403 E:7405 ||| CD
/ ||| S:7405 E:7406 ||| CD
ml ||| S:7406 E:7408 ||| CD
)  ||| S:7408 E:7410 ||| -RRB-
and  ||| S:7410 E:7414 ||| CC
CEES  ||| S:7414 E:7419 ||| NNP
( ||| S:7419 E:7420 ||| -LRB-
500  ||| S:7420 E:7424 ||| CD
μM ||| S:7424 E:7426 ||| NN
)  ||| S:7426 E:7428 ||| -RRB-
was  ||| S:7428 E:7432 ||| VBD
not  ||| S:7432 E:7436 ||| RB
found  ||| S:7436 E:7442 ||| VBN
to  ||| S:7442 E:7445 ||| TO
be  ||| S:7445 E:7448 ||| VB
more  ||| S:7448 E:7463 ||| JJR
cytotoxic  ||| S:7463 E:7473 ||| NN
than  ||| S:7473 E:7478 ||| IN
LPS  ||| S:7478 E:7482 ||| NNP
( ||| S:7482 E:7483 ||| -LRB-
25  ||| S:7483 E:7486 ||| CD
ng ||| S:7486 E:7488 ||| CD
/ ||| S:7488 E:7489 ||| CD
ml ||| S:7489 E:7491 ||| CD
)  ||| S:7491 E:7493 ||| -RRB-
and  ||| S:7493 E:7497 ||| CC
CEES  ||| S:7497 E:7502 ||| NNP
( ||| S:7502 E:7503 ||| -LRB-
500  ||| S:7503 E:7507 ||| CD
μM ||| S:7507 E:7509 ||| NN
) ||| S:7509 E:7510 ||| -RRB-
.  ||| S:7510 E:7522 ||| .
Table  ||| S:7522 E:7528 ||| NN
2shows  ||| S:7528 E:7535 ||| VBZ
completely  ||| S:7535 E:7546 ||| RB
analogous  ||| S:7546 E:7556 ||| JJ
data  ||| S:7556 E:7561 ||| NNS
with  ||| S:7561 E:7566 ||| IN
TNF-alpha ||| S:7566 E:7575 ||| NNP
,  ||| S:7575 E:7587 ||| ,
i.e. ||| S:7587 E:7591 ||| FW
,  ||| S:7591 E:7593 ||| ,
an  ||| S:7593 E:7596 ||| DT
amplification  ||| S:7596 E:7610 ||| NN
of  ||| S:7610 E:7613 ||| IN
CEES  ||| S:7613 E:7618 ||| NNP
toxicity  ||| S:7618 E:7627 ||| NNS
( ||| S:7627 E:7628 ||| -LRB-
after  ||| S:7628 E:7634 ||| IN
24  ||| S:7634 E:7637 ||| CD
hours ||| S:7637 E:7642 ||| NNS
)  ||| S:7642 E:7654 ||| -RRB-
in  ||| S:7654 E:7657 ||| IN
the  ||| S:7657 E:7661 ||| DT
presence  ||| S:7661 E:7670 ||| NN
of  ||| S:7670 E:7673 ||| IN
the  ||| S:7673 E:7677 ||| DT
inflammatory  ||| S:7677 E:7690 ||| JJ
cytokine ||| S:7690 E:7698 ||| NN
.  ||| S:7698 E:7700 ||| .
In  ||| S:7700 E:7703 ||| IN
this  ||| S:7703 E:7718 ||| DT
experiment ||| S:7718 E:7728 ||| NN
,  ||| S:7728 E:7730 ||| ,
LPS  ||| S:7730 E:7734 ||| NNP
at  ||| S:7734 E:7737 ||| IN
25  ||| S:7737 E:7740 ||| CD
ng ||| S:7740 E:7742 ||| CD
/ ||| S:7742 E:7743 ||| CD
ml  ||| S:7743 E:7746 ||| NNS
plus  ||| S:7746 E:7751 ||| CC
CEES  ||| S:7751 E:7756 ||| NNP
( ||| S:7756 E:7757 ||| -LRB-
at  ||| S:7757 E:7760 ||| IN
500  ||| S:7760 E:7764 ||| CD
μM ||| S:7764 E:7766 ||| NN
)  ||| S:7766 E:7768 ||| -RRB-
gave  ||| S:7768 E:7783 ||| VBD
PI ||| S:7783 E:7785 ||| NNP
( ||| S:7785 E:7786 ||| -LRB-
% ||| S:7786 E:7787 ||| NN
)  ||| S:7787 E:7789 ||| -RRB-
and  ||| S:7789 E:7793 ||| CC
MTT  ||| S:7793 E:7797 ||| NNP
values  ||| S:7797 E:7804 ||| NNS
of  ||| S:7804 E:7807 ||| IN
62.6  ||| S:7807 E:7812 ||| CD
±  ||| S:7812 E:7814 ||| CD
1.4  ||| S:7814 E:7818 ||| CD
and  ||| S:7818 E:7822 ||| CC
0.32  ||| S:7822 E:7827 ||| CD
±  ||| S:7827 E:7829 ||| CD
0.05 ||| S:7829 E:7833 ||| CD
,  ||| S:7833 E:7845 ||| ,
respectively ||| S:7845 E:7857 ||| RB
.  ||| S:7857 E:7859 ||| .
This  ||| S:7859 E:7864 ||| DT
indicates  ||| S:7864 E:7874 ||| VBZ
that  ||| S:7874 E:7879 ||| DT
TNF-alpha  ||| S:7879 E:7889 ||| JJ
at  ||| S:7889 E:7892 ||| IN
50  ||| S:7892 E:7895 ||| CD
ng ||| S:7895 E:7897 ||| CD
/ ||| S:7897 E:7898 ||| CD
ml  ||| S:7898 E:7911 ||| NN
is  ||| S:7911 E:7914 ||| VBZ
not  ||| S:7914 E:7918 ||| RB
as  ||| S:7918 E:7921 ||| IN
potent  ||| S:7921 E:7928 ||| JJ
at  ||| S:7928 E:7931 ||| IN
LPS  ||| S:7931 E:7935 ||| NNP
( ||| S:7935 E:7936 ||| -LRB-
at  ||| S:7936 E:7939 ||| IN
25  ||| S:7939 E:7942 ||| CD
ng ||| S:7942 E:7944 ||| CD
/ ||| S:7944 E:7945 ||| CD
ml ||| S:7945 E:7947 ||| CD
)  ||| S:7947 E:7949 ||| -RRB-
in  ||| S:7949 E:7952 ||| IN
enhancing  ||| S:7952 E:7962 ||| VBG
the  ||| S:7962 E:7976 ||| DT
cytotoxicity  ||| S:7976 E:7989 ||| NN
of  ||| S:7989 E:7992 ||| IN
CEES  ||| S:7992 E:7997 ||| NNP
at  ||| S:7997 E:8000 ||| IN
500  ||| S:8000 E:8004 ||| CD
μM ||| S:8004 E:8006 ||| NN
.  ||| S:8006 E:8008 ||| .
TNF-alpha  ||| S:8008 E:8018 ||| JJ
combined  ||| S:8018 E:8027 ||| VBN
with  ||| S:8027 E:8042 ||| IN
LPS  ||| S:8042 E:8046 ||| NNP
( ||| S:8046 E:8047 ||| -LRB-
in  ||| S:8047 E:8050 ||| IN
the  ||| S:8050 E:8054 ||| DT
absence  ||| S:8054 E:8062 ||| NN
of  ||| S:8062 E:8065 ||| IN
CEES ||| S:8065 E:8069 ||| NNP
)  ||| S:8069 E:8071 ||| -RRB-
was  ||| S:8071 E:8075 ||| VBD
found  ||| S:8075 E:8081 ||| VBN
to  ||| S:8081 E:8084 ||| TO
not  ||| S:8084 E:8088 ||| RB
exert  ||| S:8088 E:8094 ||| VB
any  ||| S:8094 E:8108 ||| DT
cytotoxic  ||| S:8108 E:8118 ||| JJ
effect  ||| S:8118 E:8125 ||| NN
on  ||| S:8125 E:8128 ||| IN
the  ||| S:8128 E:8132 ||| DT
RAW264.7  ||| S:8132 E:8141 ||| JJ
macrophages ||| S:8141 E:8152 ||| NN
.  ||| S:8152 E:8164 ||| .
Protein  ||| S:8164 E:8172 ||| NN
kinase  ||| S:8172 E:8179 ||| VBD
C  ||| S:8179 E:8181 ||| NNP
is  ||| S:8181 E:8184 ||| VBZ
a  ||| S:8184 E:8186 ||| DT
non-receptor  ||| S:8186 E:8199 ||| JJ
serine ||| S:8199 E:8205 ||| NNS
/ ||| S:8205 E:8206 ||| VBP
threonine  ||| S:8206 E:8226 ||| JJ
kinase  ||| S:8226 E:8233 ||| NN
that  ||| S:8233 E:8238 ||| WDT
is  ||| S:8238 E:8241 ||| VBZ
maximally  ||| S:8241 E:8251 ||| JJ
active  ||| S:8251 E:8258 ||| JJ
in  ||| S:8258 E:8261 ||| IN
the  ||| S:8261 E:8265 ||| DT
presence  ||| S:8265 E:8274 ||| NN
of  ||| S:8274 E:8287 ||| IN
diacylglycerol  ||| S:8287 E:8302 ||| NN
and  ||| S:8302 E:8306 ||| CC
calcium  ||| S:8306 E:8314 ||| JJ
ions ||| S:8314 E:8318 ||| NN
.  ||| S:8318 E:8331 ||| .
In  ||| S:8331 E:8334 ||| IN
vitro  ||| S:8334 E:8340 ||| JJ
experiments  ||| S:8340 E:8352 ||| NNS
by  ||| S:8352 E:8355 ||| IN
Coffey  ||| S:8355 E:8362 ||| NNP
et  ||| S:8362 E:8375 ||| FW
al.  ||| S:8375 E:8379 ||| FW
[  ||| S:8379 E:8381 ||| -LRB-
14  ||| S:8381 E:8384 ||| CD
]  ||| S:8384 E:8386 ||| -RRB-
have  ||| S:8386 E:8391 ||| VBP
shown  ||| S:8391 E:8397 ||| VBN
that  ||| S:8397 E:8402 ||| IN
TNF-alpha  ||| S:8402 E:8412 ||| JJ
and  ||| S:8412 E:8416 ||| CC
IL-1beta  ||| S:8416 E:8435 ||| CD
secretion  ||| S:8435 E:8445 ||| NNS
and  ||| S:8445 E:8449 ||| CC
mRNA  ||| S:8449 E:8454 ||| JJ
accumulation  ||| S:8454 E:8467 ||| NN
by  ||| S:8467 E:8470 ||| IN
monocytes  ||| S:8470 E:8480 ||| NNS
following  ||| S:8480 E:8500 ||| VBG
LPS  ||| S:8500 E:8504 ||| NNP
treatment  ||| S:8504 E:8514 ||| NN
is  ||| S:8514 E:8517 ||| VBZ
dependent  ||| S:8517 E:8527 ||| JJ
on  ||| S:8527 E:8530 ||| IN
PKC  ||| S:8530 E:8534 ||| NNP
activity ||| S:8534 E:8542 ||| NN
.  ||| S:8542 E:8544 ||| .
Phorbol  ||| S:8544 E:8562 ||| NNP
12-myristate  ||| S:8562 E:8575 ||| NNP
13-acetate  ||| S:8575 E:8586 ||| NNP
( ||| S:8586 E:8587 ||| -LRB-
PMA ||| S:8587 E:8590 ||| NNP
)  ||| S:8590 E:8592 ||| -RRB-
is  ||| S:8592 E:8595 ||| VBZ
a  ||| S:8595 E:8597 ||| DT
specific  ||| S:8597 E:8606 ||| JJ
activator  ||| S:8606 E:8616 ||| NN
of  ||| S:8616 E:8629 ||| IN
group  ||| S:8629 E:8635 ||| NN
A  ||| S:8635 E:8637 ||| NN
and  ||| S:8637 E:8641 ||| CC
group  ||| S:8641 E:8647 ||| NN
B  ||| S:8647 E:8649 ||| NN
protein  ||| S:8649 E:8657 ||| NN
kinase  ||| S:8657 E:8664 ||| VBD
C.  ||| S:8664 E:8667 ||| NNP
We  ||| S:8667 E:8670 ||| PRP
wanted  ||| S:8670 E:8677 ||| VBD
to  ||| S:8677 E:8690 ||| TO
determine ||| S:8690 E:8699 ||| VB
,  ||| S:8699 E:8701 ||| ,
therefore ||| S:8701 E:8710 ||| RB
,  ||| S:8710 E:8712 ||| ,
if  ||| S:8712 E:8715 ||| IN
protein  ||| S:8715 E:8723 ||| NN
kinase  ||| S:8723 E:8730 ||| VBD
C  ||| S:8730 E:8732 ||| $
activation  ||| S:8732 E:8743 ||| CD
by  ||| S:8743 E:8756 ||| IN
PMA  ||| S:8756 E:8760 ||| NNP
would  ||| S:8760 E:8766 ||| MD
enhance  ||| S:8766 E:8774 ||| VB
the  ||| S:8774 E:8778 ||| DT
toxicity  ||| S:8778 E:8787 ||| NN
of  ||| S:8787 E:8790 ||| IN
CEES ||| S:8790 E:8794 ||| NNP
.  ||| S:8794 E:8796 ||| .
As  ||| S:8796 E:8799 ||| RB
shown  ||| S:8799 E:8805 ||| VBN
in  ||| S:8805 E:8808 ||| IN
Table  ||| S:8808 E:8824 ||| NNP
3 ||| S:8824 E:8825 ||| CD
,  ||| S:8825 E:8827 ||| ,
the  ||| S:8827 E:8831 ||| DT
combination  ||| S:8831 E:8843 ||| NN
of  ||| S:8843 E:8846 ||| IN
PMA  ||| S:8846 E:8850 ||| NNP
( ||| S:8850 E:8851 ||| -LRB-
50  ||| S:8851 E:8854 ||| CD
ng ||| S:8854 E:8856 ||| CD
/ ||| S:8856 E:8857 ||| CD
ml ||| S:8857 E:8859 ||| CD
)  ||| S:8859 E:8861 ||| -RRB-
and  ||| S:8861 E:8865 ||| CC
CEES  ||| S:8865 E:8870 ||| NNP
( ||| S:8870 E:8871 ||| -LRB-
500  ||| S:8871 E:8875 ||| CD
μM ||| S:8875 E:8877 ||| NN
)  ||| S:8877 E:8889 ||| -RRB-
was  ||| S:8889 E:8893 ||| VBD
more  ||| S:8893 E:8898 ||| JJR
cytotoxic  ||| S:8898 E:8908 ||| NNS
( ||| S:8908 E:8909 ||| -LRB-
after  ||| S:8909 E:8915 ||| IN
24  ||| S:8915 E:8918 ||| CD
hours ||| S:8918 E:8923 ||| NNS
)  ||| S:8923 E:8925 ||| -RRB-
toward  ||| S:8925 E:8932 ||| IN
the  ||| S:8932 E:8936 ||| DT
RAW264.7  ||| S:8936 E:8955 ||| JJ
macrophages  ||| S:8955 E:8967 ||| NN
than  ||| S:8967 E:8972 ||| IN
LPS  ||| S:8972 E:8976 ||| NNP
or  ||| S:8976 E:8979 ||| CC
CEES  ||| S:8979 E:8984 ||| NNP
alone ||| S:8984 E:8989 ||| RB
.  ||| S:8989 E:8991 ||| .
However ||| S:8991 E:8998 ||| RB
,  ||| S:8998 E:9000 ||| ,
as  ||| S:9000 E:9003 ||| RB
was  ||| S:9003 E:9007 ||| VBD
the  ||| S:9007 E:9021 ||| DT
case  ||| S:9021 E:9026 ||| NN
with  ||| S:9026 E:9031 ||| IN
IL-1beta  ||| S:9031 E:9040 ||| NNP
and  ||| S:9040 E:9044 ||| CC
TNF-alpha ||| S:9044 E:9053 ||| JJ
,  ||| S:9053 E:9055 ||| ,
PMA  ||| S:9055 E:9059 ||| NNP
was  ||| S:9059 E:9063 ||| VBD
not  ||| S:9063 E:9067 ||| RB
as  ||| S:9067 E:9080 ||| IN
effective  ||| S:9080 E:9090 ||| JJ
as  ||| S:9090 E:9093 ||| IN
LPS  ||| S:9093 E:9097 ||| NNP
in  ||| S:9097 E:9100 ||| IN
enhancing  ||| S:9100 E:9110 ||| VBG
CEES  ||| S:9110 E:9115 ||| NNP
toxicity ||| S:9115 E:9123 ||| NN
.  ||| S:9123 E:9156 ||| .
Discussion  ||| S:9156 E:9175 ||| NN
We  ||| S:9175 E:9178 ||| PRP
have  ||| S:9178 E:9183 ||| VBP
found  ||| S:9183 E:9189 ||| VBN
that  ||| S:9189 E:9194 ||| IN
inflammatory  ||| S:9194 E:9207 ||| JJ
agents  ||| S:9207 E:9214 ||| NNS
such  ||| S:9214 E:9219 ||| JJ
as  ||| S:9219 E:9222 ||| IN
LPS ||| S:9222 E:9225 ||| NNP
,  ||| S:9225 E:9235 ||| ,
TNF-alpha ||| S:9235 E:9244 ||| NNP
,  ||| S:9244 E:9246 ||| ,
IL-1beta ||| S:9246 E:9254 ||| NNP
,  ||| S:9254 E:9256 ||| ,
and  ||| S:9256 E:9260 ||| CC
PMA  ||| S:9260 E:9264 ||| NNP
amplify  ||| S:9264 E:9272 ||| VBD
the  ||| S:9272 E:9276 ||| DT
cytotoxicity  ||| S:9276 E:9289 ||| NN
of  ||| S:9289 E:9300 ||| IN
CEES  ||| S:9300 E:9305 ||| NNP
to  ||| S:9305 E:9308 ||| TO
RAW264.7  ||| S:9308 E:9317 ||| CD
macrophages ||| S:9317 E:9328 ||| NNS
.  ||| S:9328 E:9330 ||| .
There  ||| S:9330 E:9336 ||| EX
is  ||| S:9336 E:9339 ||| VBZ
evidence  ||| S:9339 E:9348 ||| NN
suggesting  ||| S:9348 E:9367 ||| VBG
that  ||| S:9367 E:9372 ||| IN
CEES  ||| S:9372 E:9377 ||| NNP
can  ||| S:9377 E:9381 ||| MD
modulate  ||| S:9381 E:9390 ||| VB
levels  ||| S:9390 E:9397 ||| NNS
of  ||| S:9397 E:9400 ||| IN
inflammatory  ||| S:9400 E:9413 ||| JJ
cytokines  ||| S:9413 E:9423 ||| NN
but  ||| S:9423 E:9435 ||| CC
this  ||| S:9435 E:9440 ||| DT
information  ||| S:9440 E:9452 ||| NN
is  ||| S:9452 E:9455 ||| VBZ
controversial  ||| S:9455 E:9469 ||| JJ
and  ||| S:9469 E:9473 ||| CC
inconsistent ||| S:9473 E:9485 ||| JJ
.  ||| S:9485 E:9495 ||| .
Cultured  ||| S:9495 E:9504 ||| NNP
monocytes  ||| S:9504 E:9514 ||| VBD
exposed  ||| S:9514 E:9522 ||| VBN
to  ||| S:9522 E:9525 ||| TO
CEES  ||| S:9525 E:9530 ||| NNP
show  ||| S:9530 E:9535 ||| VBP
a  ||| S:9535 E:9537 ||| DT
transient  ||| S:9537 E:9555 ||| JJ
increase  ||| S:9555 E:9564 ||| NN
in  ||| S:9564 E:9567 ||| IN
TNF-alpha  ||| S:9567 E:9577 ||| NNP
[  ||| S:9577 E:9579 ||| -LRB-
18  ||| S:9579 E:9582 ||| CD
]  ||| S:9582 E:9584 ||| -RRB-
.  ||| S:9584 E:9586 ||| .
Similarly ||| S:9586 E:9595 ||| RB
,  ||| S:9595 E:9597 ||| ,
cultured  ||| S:9597 E:9606 ||| JJ
normal  ||| S:9606 E:9621 ||| JJ
human  ||| S:9621 E:9627 ||| JJ
keratinocytes  ||| S:9627 E:9641 ||| NNS
exposed  ||| S:9641 E:9649 ||| VBN
to  ||| S:9649 E:9652 ||| TO
CEES  ||| S:9652 E:9657 ||| NNP
show  ||| S:9657 E:9662 ||| VBP
a  ||| S:9662 E:9664 ||| DT
transient  ||| S:9664 E:9682 ||| JJ
increase  ||| S:9682 E:9691 ||| NN
in  ||| S:9691 E:9694 ||| IN
both  ||| S:9694 E:9699 ||| DT
TNF-alpha  ||| S:9699 E:9709 ||| JJ
and  ||| S:9709 E:9713 ||| CC
IL-1beta  ||| S:9713 E:9722 ||| NNP
[  ||| S:9722 E:9724 ||| -LRB-
19  ||| S:9724 E:9727 ||| CD
20  ||| S:9727 E:9730 ||| CD
]  ||| S:9730 E:9732 ||| -RRB-
.  ||| S:9732 E:9734 ||| .
In  ||| S:9734 E:9745 ||| IN
contrast  ||| S:9745 E:9754 ||| NN
to  ||| S:9754 E:9757 ||| TO
the  ||| S:9757 E:9761 ||| DT
results  ||| S:9761 E:9769 ||| NNS
of  ||| S:9769 E:9772 ||| IN
Arroyo  ||| S:9772 E:9779 ||| NNP
et  ||| S:9779 E:9782 ||| FW
al.  ||| S:9782 E:9786 ||| FW
[  ||| S:9786 E:9788 ||| -LRB-
18  ||| S:9788 E:9791 ||| CD
19  ||| S:9791 E:9794 ||| CD
20  ||| S:9794 E:9797 ||| CD
]  ||| S:9797 E:9799 ||| -RRB-
,  ||| S:9799 E:9809 ||| ,
Ricketts  ||| S:9809 E:9818 ||| FW
et  ||| S:9818 E:9821 ||| FW
al.  ||| S:9821 E:9825 ||| FW
[  ||| S:9825 E:9827 ||| -LRB-
21  ||| S:9827 E:9830 ||| CD
]  ||| S:9830 E:9832 ||| -RRB-
found  ||| S:9832 E:9838 ||| VBD
that  ||| S:9838 E:9843 ||| IN
IL-1beta  ||| S:9843 E:9852 ||| NNP
or  ||| S:9852 E:9855 ||| CC
TNF-alpha  ||| S:9855 E:9873 ||| JJ
protein  ||| S:9873 E:9881 ||| NN
did  ||| S:9881 E:9885 ||| VBD
not  ||| S:9885 E:9889 ||| RB
increase  ||| S:9889 E:9898 ||| VB
in  ||| S:9898 E:9901 ||| IN
sulfur  ||| S:9901 E:9908 ||| JJ
mustard-exposed  ||| S:9908 E:9924 ||| JJ
mouse  ||| S:9924 E:9938 ||| NN
skin ||| S:9938 E:9942 ||| NN
.  ||| S:9942 E:9944 ||| .
Blaha  ||| S:9944 E:9950 ||| FW
et  ||| S:9950 E:9953 ||| FW
al.  ||| S:9953 E:9957 ||| FW
[  ||| S:9957 E:9959 ||| -LRB-
1  ||| S:9959 E:9961 ||| LS
]  ||| S:9961 E:9963 ||| -RRB-
,  ||| S:9963 E:9965 ||| ,
using  ||| S:9965 E:9971 ||| VBG
an  ||| S:9971 E:9983 ||| DT
in  ||| S:9983 E:9986 ||| IN
vitro  ||| S:9986 E:9992 ||| JJ
human  ||| S:9992 E:9998 ||| JJ
skin  ||| S:9998 E:10003 ||| NN
model ||| S:10003 E:10008 ||| NN
,  ||| S:10008 E:10010 ||| ,
found  ||| S:10010 E:10016 ||| VBN
that  ||| S:10016 E:10029 ||| IN
CEES  ||| S:10029 E:10034 ||| NNP
treatment  ||| S:10034 E:10044 ||| NN
resulted  ||| S:10044 E:10053 ||| VBD
in  ||| S:10053 E:10056 ||| IN
a  ||| S:10056 E:10058 ||| DT
decreased  ||| S:10058 E:10068 ||| JJ
level  ||| S:10068 E:10074 ||| NN
of  ||| S:10074 E:10085 ||| IN
IL-1alpha ||| S:10085 E:10094 ||| CD
.  ||| S:10094 E:10104 ||| .
Sabourin  ||| S:10104 E:10113 ||| FW
et  ||| S:10113 E:10116 ||| FW
al.  ||| S:10116 E:10120 ||| FW
[  ||| S:10120 E:10122 ||| -LRB-
3  ||| S:10122 E:10124 ||| LS
]  ||| S:10124 E:10126 ||| -RRB-
also  ||| S:10126 E:10131 ||| RB
addressed  ||| S:10131 E:10141 ||| VBN
this  ||| S:10141 E:10146 ||| DT
issue  ||| S:10146 E:10152 ||| NN
and  ||| S:10152 E:10164 ||| CC
studied  ||| S:10164 E:10172 ||| VBD
the  ||| S:10172 E:10185 ||| DT
in  ||| S:10185 E:10188 ||| IN
vivo  ||| S:10188 E:10193 ||| JJ
temporal  ||| S:10193 E:10202 ||| JJ
sequence  ||| S:10202 E:10211 ||| NN
of  ||| S:10211 E:10222 ||| IN
inflammatory  ||| S:10222 E:10235 ||| JJ
cytokine  ||| S:10235 E:10244 ||| JJ
gene  ||| S:10244 E:10249 ||| NN
expression  ||| S:10249 E:10260 ||| NN
in  ||| S:10260 E:10263 ||| IN
sulfur  ||| S:10263 E:10270 ||| JJ
mustard  ||| S:10270 E:10286 ||| NN
exposed  ||| S:10286 E:10294 ||| VBN
mouse  ||| S:10294 E:10300 ||| NN
skin ||| S:10300 E:10304 ||| NN
.  ||| S:10304 E:10306 ||| .
These  ||| S:10306 E:10312 ||| DT
investigators  ||| S:10312 E:10326 ||| NNS
found  ||| S:10326 E:10332 ||| VBD
an  ||| S:10332 E:10335 ||| DT
increase  ||| S:10335 E:10352 ||| NN
in  ||| S:10352 E:10355 ||| IN
IL-1beta  ||| S:10355 E:10364 ||| CD
mRNA  ||| S:10364 E:10369 ||| JJ
levels  ||| S:10369 E:10376 ||| NNS
after  ||| S:10376 E:10382 ||| IN
3  ||| S:10382 E:10384 ||| CD
hours  ||| S:10384 E:10390 ||| NNS
that  ||| S:10390 E:10395 ||| WDT
dramatically  ||| S:10395 E:10416 ||| RB
increased  ||| S:10416 E:10426 ||| VBN
between  ||| S:10426 E:10434 ||| IN
6-24  ||| S:10434 E:10439 ||| CD
hours  ||| S:10439 E:10445 ||| NNS
post  ||| S:10445 E:10450 ||| NN
exposure  ||| S:10450 E:10459 ||| NN
[  ||| S:10459 E:10461 ||| -LRB-
3  ||| S:10461 E:10463 ||| LS
]  ||| S:10463 E:10465 ||| -RRB-
.  ||| S:10465 E:10475 ||| .
Moreover ||| S:10475 E:10483 ||| RB
,  ||| S:10483 E:10485 ||| ,
immunohistochemical  ||| S:10485 E:10505 ||| JJ
studies  ||| S:10505 E:10513 ||| NNS
showed  ||| S:10513 E:10520 ||| VBD
an  ||| S:10520 E:10523 ||| DT
increase  ||| S:10523 E:10532 ||| NN
in  ||| S:10532 E:10543 ||| IN
tissue  ||| S:10543 E:10550 ||| NN
levels  ||| S:10550 E:10557 ||| NNS
of  ||| S:10557 E:10560 ||| IN
IL-1beta  ||| S:10560 E:10569 ||| NNP
[  ||| S:10569 E:10571 ||| -LRB-
3  ||| S:10571 E:10573 ||| LS
]  ||| S:10573 E:10575 ||| -RRB-
.  ||| S:10575 E:10577 ||| .
The  ||| S:10577 E:10590 ||| DT
in  ||| S:10590 E:10593 ||| IN
vitro  ||| S:10593 E:10599 ||| JJ
results  ||| S:10599 E:10607 ||| NNS
reported  ||| S:10607 E:10616 ||| VBD
here  ||| S:10616 E:10629 ||| RB
support  ||| S:10629 E:10637 ||| VB
a  ||| S:10637 E:10639 ||| DT
role  ||| S:10639 E:10644 ||| NN
for  ||| S:10644 E:10648 ||| IN
inflammatory  ||| S:10648 E:10661 ||| JJ
cytokines  ||| S:10661 E:10671 ||| NN
in  ||| S:10671 E:10674 ||| IN
the  ||| S:10674 E:10678 ||| DT
mechanism  ||| S:10678 E:10696 ||| NN
and  ||| S:10696 E:10700 ||| CC
kinetics  ||| S:10700 E:10709 ||| NN
of  ||| S:10709 E:10712 ||| IN
CEES  ||| S:10712 E:10717 ||| NNP
toxicity ||| S:10717 E:10725 ||| NN
.  ||| S:10725 E:10727 ||| .
Our  ||| S:10727 E:10731 ||| PRP$
unique  ||| S:10731 E:10738 ||| JJ
findings  ||| S:10738 E:10747 ||| NNS
with  ||| S:10747 E:10760 ||| IN
regards  ||| S:10760 E:10768 ||| VBG
to  ||| S:10768 E:10771 ||| TO
LPS  ||| S:10771 E:10775 ||| NNP
are  ||| S:10775 E:10779 ||| VBP
significant  ||| S:10779 E:10791 ||| JJ
because  ||| S:10791 E:10799 ||| IN
they  ||| S:10799 E:10804 ||| PRP
demonstrate  ||| S:10804 E:10824 ||| VBP
that  ||| S:10824 E:10829 ||| IN
this  ||| S:10829 E:10834 ||| DT
bacterial  ||| S:10834 E:10844 ||| JJ
endotoxin  ||| S:10844 E:10854 ||| NN
enhances  ||| S:10854 E:10863 ||| VBZ
CEES  ||| S:10863 E:10868 ||| NNP
toxicity  ||| S:10868 E:10877 ||| VBD
even  ||| S:10877 E:10890 ||| RB
when  ||| S:10890 E:10895 ||| WRB
present  ||| S:10895 E:10903 ||| JJ
at  ||| S:10903 E:10906 ||| IN
extremely  ||| S:10906 E:10916 ||| RB
low  ||| S:10916 E:10920 ||| JJ
levels ||| S:10920 E:10926 ||| NNS
,  ||| S:10926 E:10928 ||| ,
i.e. ||| S:10928 E:10932 ||| FW
,  ||| S:10932 E:10934 ||| ,
nanograms  ||| S:10934 E:10944 ||| VBG
of  ||| S:10944 E:10955 ||| IN
LPS  ||| S:10955 E:10959 ||| NNP
per  ||| S:10959 E:10963 ||| FW
ml ||| S:10963 E:10965 ||| FW
.  ||| S:10965 E:10975 ||| .
LPS  ||| S:10975 E:10979 ||| NNP
is  ||| S:10979 E:10982 ||| VBZ
ubiquitous  ||| S:10982 E:10993 ||| JJ
and  ||| S:10993 E:10997 ||| CC
is  ||| S:10997 E:11000 ||| VBZ
present  ||| S:11000 E:11008 ||| JJ
in  ||| S:11008 E:11011 ||| IN
serum ||| S:11011 E:11016 ||| NN
,  ||| S:11016 E:11018 ||| ,
tap  ||| S:11018 E:11022 ||| JJ
water ||| S:11022 E:11027 ||| NN
,  ||| S:11027 E:11037 ||| ,
and  ||| S:11037 E:11041 ||| CC
dust ||| S:11041 E:11045 ||| NN
.  ||| S:11045 E:11047 ||| .
Military  ||| S:11047 E:11056 ||| JJ
and  ||| S:11056 E:11060 ||| CC
civilian  ||| S:11060 E:11069 ||| JJ
personnel  ||| S:11069 E:11079 ||| NNS
would ||| S:11079 E:11084 ||| MD
,  ||| S:11084 E:11086 ||| ,
indeed ||| S:11086 E:11092 ||| RB
,  ||| S:11092 E:11102 ||| ,
always  ||| S:11102 E:11109 ||| RB
have  ||| S:11109 E:11114 ||| VB
some  ||| S:11114 E:11119 ||| DT
degree  ||| S:11119 E:11126 ||| NN
of  ||| S:11126 E:11129 ||| IN
exposure  ||| S:11129 E:11138 ||| NN
to  ||| S:11138 E:11141 ||| TO
environmental  ||| S:11141 E:11155 ||| JJ
LPS ||| S:11155 E:11158 ||| NNP
,  ||| S:11158 E:11168 ||| ,
which  ||| S:11168 E:11174 ||| WDT
could  ||| S:11174 E:11180 ||| MD
increase  ||| S:11180 E:11189 ||| VB
the  ||| S:11189 E:11193 ||| DT
toxicity  ||| S:11193 E:11202 ||| NN
of  ||| S:11202 E:11205 ||| IN
sulfur  ||| S:11205 E:11212 ||| JJ
mustard ||| S:11212 E:11219 ||| NN
.  ||| S:11219 E:11221 ||| .
In  ||| S:11221 E:11232 ||| IN
addition ||| S:11232 E:11240 ||| NN
,  ||| S:11240 E:11242 ||| ,
there  ||| S:11242 E:11248 ||| EX
is  ||| S:11248 E:11251 ||| VBZ
always  ||| S:11251 E:11258 ||| RB
the  ||| S:11258 E:11262 ||| DT
possibility  ||| S:11262 E:11274 ||| NN
of  ||| S:11274 E:11277 ||| IN
purposeful  ||| S:11277 E:11288 ||| JJ
LPS  ||| S:11288 E:11300 ||| NNP
exposure ||| S:11300 E:11308 ||| NN
.  ||| S:11308 E:11310 ||| .
Our  ||| S:11310 E:11314 ||| PRP$
primary  ||| S:11314 E:11322 ||| JJ
future  ||| S:11322 E:11329 ||| JJ
goals  ||| S:11329 E:11335 ||| NNS
are  ||| S:11335 E:11339 ||| VBP
to  ||| S:11339 E:11342 ||| TO
understand  ||| S:11342 E:11353 ||| VB
the  ||| S:11353 E:11365 ||| DT
general  ||| S:11365 E:11373 ||| JJ
mechanism  ||| S:11373 E:11383 ||| NN
for  ||| S:11383 E:11387 ||| IN
the  ||| S:11387 E:11391 ||| DT
enhanced  ||| S:11391 E:11400 ||| JJ
toxicity  ||| S:11400 E:11409 ||| NN
of  ||| S:11409 E:11412 ||| IN
CEES  ||| S:11412 E:11417 ||| NNP
in  ||| S:11417 E:11420 ||| IN
the  ||| S:11420 E:11432 ||| DT
presence  ||| S:11432 E:11441 ||| NN
of  ||| S:11441 E:11444 ||| IN
inflammatory  ||| S:11444 E:11457 ||| JJ
agents  ||| S:11457 E:11464 ||| NNS
and  ||| S:11464 E:11468 ||| CC
use  ||| S:11468 E:11472 ||| VB
this  ||| S:11472 E:11477 ||| DT
information  ||| S:11477 E:11489 ||| NN
to  ||| S:11489 E:11500 ||| TO
develop  ||| S:11500 E:11508 ||| VB
effective  ||| S:11508 E:11518 ||| JJ
countermeasures ||| S:11518 E:11533 ||| NNS
.  ||| S:11533 E:11535 ||| .
Our  ||| S:11535 E:11539 ||| PRP$
experiments  ||| S:11539 E:11551 ||| NNS
with  ||| S:11551 E:11556 ||| IN
PMA  ||| S:11556 E:11568 ||| NNP
( ||| S:11568 E:11569 ||| -LRB-
Table  ||| S:11569 E:11575 ||| NNP
3 ||| S:11575 E:11576 ||| CD
)  ||| S:11576 E:11578 ||| -RRB-
suggest  ||| S:11578 E:11586 ||| VBP
that  ||| S:11586 E:11591 ||| IN
the  ||| S:11591 E:11595 ||| DT
activation  ||| S:11595 E:11606 ||| NN
of  ||| S:11606 E:11609 ||| IN
protein  ||| S:11609 E:11617 ||| NN
kinase  ||| S:11617 E:11624 ||| VBD
C  ||| S:11624 E:11634 ||| NNP
may  ||| S:11634 E:11638 ||| MD
play  ||| S:11638 E:11643 ||| VB
a  ||| S:11643 E:11645 ||| DT
key  ||| S:11645 E:11649 ||| JJ
role  ||| S:11649 E:11654 ||| NN
in  ||| S:11654 E:11657 ||| IN
molecular  ||| S:11657 E:11667 ||| JJ
mechanism  ||| S:11667 E:11677 ||| NN
whereby  ||| S:11677 E:11685 ||| WRB
LPS  ||| S:11685 E:11697 ||| NNP
enhances  ||| S:11697 E:11706 ||| VBZ
the  ||| S:11706 E:11710 ||| DT
cytotoxic  ||| S:11710 E:11720 ||| NN
of  ||| S:11720 E:11723 ||| IN
CEES ||| S:11723 E:11727 ||| NNP
.  ||| S:11727 E:11737 ||| .
In  ||| S:11737 E:11740 ||| IN
experiments  ||| S:11740 E:11752 ||| NNS
that  ||| S:11752 E:11757 ||| WDT
will  ||| S:11757 E:11762 ||| MD
be  ||| S:11762 E:11765 ||| VB
reported  ||| S:11765 E:11774 ||| VBN
elsewhere ||| S:11774 E:11783 ||| RB
,  ||| S:11783 E:11785 ||| ,
we  ||| S:11785 E:11788 ||| PRP
have  ||| S:11788 E:11801 ||| VBP
found  ||| S:11801 E:11807 ||| VBN
the  ||| S:11807 E:11811 ||| DT
antioxidants  ||| S:11811 E:11824 ||| JJ
such  ||| S:11824 E:11829 ||| JJ
as  ||| S:11829 E:11832 ||| IN
RRR-alpha-tocopherol  ||| S:11832 E:11853 ||| JJ
and  ||| S:11853 E:11865 ||| CC
N-acetylcysteine  ||| S:11865 E:11882 ||| NNS
are  ||| S:11882 E:11886 ||| VBP
effective  ||| S:11886 E:11896 ||| JJ
in  ||| S:11896 E:11899 ||| IN
reducing  ||| S:11899 E:11908 ||| VBG
the  ||| S:11908 E:11912 ||| DT
cytotoxic  ||| S:11912 E:11930 ||| JJ
effects  ||| S:11930 E:11938 ||| NNS
of  ||| S:11938 E:11941 ||| IN
CEES  ||| S:11941 E:11946 ||| NNP
on  ||| S:11946 E:11949 ||| IN
LPS-stimulated  ||| S:11949 E:11964 ||| JJ
macrophages ||| S:11964 E:11975 ||| NN
.  ||| S:11975 E:11977 ||| .
We  ||| S:11977 E:11980 ||| PRP
have  ||| S:11980 E:11985 ||| VBP
also  ||| S:11985 E:11998 ||| RB
initiated  ||| S:11998 E:12008 ||| VBN
experiments  ||| S:12008 E:12020 ||| NNS
to  ||| S:12020 E:12023 ||| TO
distinguish  ||| S:12023 E:12035 ||| VB
the  ||| S:12035 E:12039 ||| DT
roles  ||| S:12039 E:12045 ||| NNS
of  ||| S:12045 E:12048 ||| IN
apoptosis  ||| S:12048 E:12066 ||| NN
and  ||| S:12066 E:12070 ||| CC
necrosis  ||| S:12070 E:12079 ||| NN
in  ||| S:12079 E:12082 ||| IN
the  ||| S:12082 E:12086 ||| DT
observation  ||| S:12086 E:12098 ||| NN
reported  ||| S:12098 E:12107 ||| VBD
here ||| S:12107 E:12111 ||| RB
.  ||| S:12111 E:12135 ||| .
Conclusions  ||| S:12135 E:12155 ||| VBG
Our  ||| S:12155 E:12159 ||| PRP$
results  ||| S:12159 E:12167 ||| NNS
suggest  ||| S:12167 E:12175 ||| VBP
that  ||| S:12175 E:12180 ||| IN
that  ||| S:12180 E:12185 ||| DT
LPS  ||| S:12185 E:12189 ||| NNP
dramatically  ||| S:12189 E:12202 ||| RB
enhances  ||| S:12202 E:12219 ||| VBZ
the  ||| S:12219 E:12223 ||| DT
toxicity  ||| S:12223 E:12232 ||| NN
of  ||| S:12232 E:12235 ||| IN
sulfur  ||| S:12235 E:12242 ||| JJ
mustard ||| S:12242 E:12249 ||| NN
.  ||| S:12249 E:12251 ||| .
Since  ||| S:12251 E:12257 ||| IN
LPS  ||| S:12257 E:12261 ||| NNP
is  ||| S:12261 E:12264 ||| VBZ
a  ||| S:12264 E:12266 ||| DT
ubiquitous  ||| S:12266 E:12285 ||| JJ
agent  ||| S:12285 E:12291 ||| NN
in  ||| S:12291 E:12294 ||| IN
the  ||| S:12294 E:12298 ||| DT
natural  ||| S:12298 E:12306 ||| JJ
environment ||| S:12306 E:12317 ||| NN
,  ||| S:12317 E:12319 ||| ,
its  ||| S:12319 E:12323 ||| PRP$
presence  ||| S:12323 E:12332 ||| NN
is  ||| S:12332 E:12335 ||| VBZ
likely  ||| S:12335 E:12342 ||| JJ
to  ||| S:12342 E:12353 ||| TO
be  ||| S:12353 E:12356 ||| VB
an  ||| S:12356 E:12359 ||| DT
important  ||| S:12359 E:12369 ||| JJ
variable  ||| S:12369 E:12378 ||| NN
influencing  ||| S:12378 E:12390 ||| VBG
the  ||| S:12390 E:12394 ||| DT
cytotoxicity  ||| S:12394 E:12407 ||| NN
of  ||| S:12407 E:12418 ||| IN
sulfur  ||| S:12418 E:12425 ||| JJ
mustard  ||| S:12425 E:12433 ||| NN
toxicity ||| S:12433 E:12441 ||| NN
.  ||| S:12441 E:12443 ||| .
LPS  ||| S:12443 E:12447 ||| NNP
is  ||| S:12447 E:12450 ||| VBZ
known  ||| S:12450 E:12456 ||| VBN
to  ||| S:12456 E:12459 ||| TO
stimulate  ||| S:12459 E:12469 ||| VB
the  ||| S:12469 E:12481 ||| DT
production  ||| S:12481 E:12492 ||| NN
of  ||| S:12492 E:12495 ||| IN
inflammatory  ||| S:12495 E:12508 ||| JJ
cytokines  ||| S:12508 E:12518 ||| JJ
such  ||| S:12518 E:12523 ||| JJ
as  ||| S:12523 E:12526 ||| IN
TNF-alpha  ||| S:12526 E:12536 ||| JJ
and  ||| S:12536 E:12548 ||| CC
IL-1beta  ||| S:12548 E:12557 ||| CD
in  ||| S:12557 E:12560 ||| IN
human  ||| S:12560 E:12566 ||| JJ
monocytes  ||| S:12566 E:12576 ||| NNS
[  ||| S:12576 E:12578 ||| -LRB-
10  ||| S:12578 E:12581 ||| CD
]  ||| S:12581 E:12583 ||| -RRB-
.  ||| S:12583 E:12585 ||| .
We ||| S:12585 E:12587 ||| PRP
,  ||| S:12587 E:12589 ||| ,
therefore ||| S:12589 E:12598 ||| RB
,  ||| S:12598 E:12600 ||| ,
also  ||| S:12600 E:12613 ||| RB
determined  ||| S:12613 E:12624 ||| VBN
if  ||| S:12624 E:12627 ||| IN
these  ||| S:12627 E:12633 ||| DT
cytokines  ||| S:12633 E:12643 ||| NN
influenced  ||| S:12643 E:12654 ||| VBD
the  ||| S:12654 E:12658 ||| DT
cytotoxicity  ||| S:12658 E:12679 ||| NN
of  ||| S:12679 E:12682 ||| IN
CEES ||| S:12682 E:12686 ||| NNP
.  ||| S:12686 E:12688 ||| .
The  ||| S:12688 E:12692 ||| DT
data  ||| S:12692 E:12697 ||| NNS
in  ||| S:12697 E:12700 ||| IN
Tables  ||| S:12700 E:12707 ||| NNP
1and  ||| S:12707 E:12712 ||| NNP
2demonstrate  ||| S:12712 E:12725 ||| NNP
that  ||| S:12725 E:12730 ||| IN
both  ||| S:12730 E:12743 ||| PDT
these  ||| S:12743 E:12749 ||| DT
cytokines  ||| S:12749 E:12759 ||| NN
enhance  ||| S:12759 E:12767 ||| VB
the  ||| S:12767 E:12771 ||| DT
cytotoxicity  ||| S:12771 E:12784 ||| NN
of  ||| S:12784 E:12787 ||| IN
CEES  ||| S:12787 E:12792 ||| NNP
as  ||| S:12792 E:12803 ||| RB
measured  ||| S:12803 E:12812 ||| VBN
by  ||| S:12812 E:12815 ||| IN
either  ||| S:12815 E:12822 ||| RB
the  ||| S:12822 E:12826 ||| DT
MTT  ||| S:12826 E:12830 ||| NNP
assay  ||| S:12830 E:12836 ||| NN
or  ||| S:12836 E:12839 ||| CC
the  ||| S:12839 E:12843 ||| DT
PI  ||| S:12843 E:12846 ||| NNP
assay ||| S:12846 E:12851 ||| NN
.  ||| S:12851 E:12861 ||| .
Inhibition  ||| S:12861 E:12872 ||| NNP
of  ||| S:12872 E:12875 ||| IN
protein  ||| S:12875 E:12883 ||| NN
kinase  ||| S:12883 E:12890 ||| VBD
C  ||| S:12890 E:12892 ||| NNP
is  ||| S:12892 E:12895 ||| VBZ
known  ||| S:12895 E:12901 ||| VBN
to  ||| S:12901 E:12904 ||| TO
block  ||| S:12904 E:12910 ||| VB
the  ||| S:12910 E:12922 ||| DT
secretion  ||| S:12922 E:12932 ||| NN
of  ||| S:12932 E:12935 ||| IN
TNF-alpha  ||| S:12935 E:12945 ||| JJ
and  ||| S:12945 E:12949 ||| CC
IL-1beta  ||| S:12949 E:12958 ||| NNP
[  ||| S:12958 E:12960 ||| -LRB-
10  ||| S:12960 E:12963 ||| CD
]  ||| S:12963 E:12965 ||| -RRB-
whereas  ||| S:12965 E:12981 ||| IN
stimulation  ||| S:12981 E:12993 ||| NN
of  ||| S:12993 E:12996 ||| IN
protein  ||| S:12996 E:13004 ||| NN
kinase  ||| S:13004 E:13011 ||| VBD
C  ||| S:13011 E:13013 ||| NNP
promotes  ||| S:13013 E:13022 ||| VBZ
TNF-alpha  ||| S:13022 E:13032 ||| JJ
and  ||| S:13032 E:13044 ||| CC
IL-1beta  ||| S:13044 E:13053 ||| CD
production  ||| S:13053 E:13064 ||| NN
[  ||| S:13064 E:13066 ||| -LRB-
22  ||| S:13066 E:13069 ||| CD
]  ||| S:13069 E:13071 ||| -RRB-
.  ||| S:13071 E:13073 ||| .
The  ||| S:13073 E:13077 ||| DT
data  ||| S:13077 E:13082 ||| NNS
reported  ||| S:13082 E:13091 ||| VBD
in  ||| S:13091 E:13094 ||| IN
Table  ||| S:13094 E:13108 ||| NNP
3show  ||| S:13108 E:13114 ||| NNP
that  ||| S:13114 E:13119 ||| IN
stimulation  ||| S:13119 E:13131 ||| NN
of  ||| S:13131 E:13134 ||| IN
protein  ||| S:13134 E:13142 ||| NN
kinase  ||| S:13142 E:13149 ||| VBD
C  ||| S:13149 E:13151 ||| NNP
activity  ||| S:13151 E:13160 ||| NN
by  ||| S:13160 E:13163 ||| IN
PMA  ||| S:13163 E:13175 ||| NNP
also  ||| S:13175 E:13180 ||| RB
enhances  ||| S:13180 E:13189 ||| VBZ
the  ||| S:13189 E:13193 ||| DT
cytotoxicity  ||| S:13193 E:13206 ||| NN
of  ||| S:13206 E:13209 ||| IN
CEES ||| S:13209 E:13213 ||| NNP
.  ||| S:13213 E:13215 ||| .
Collectively ||| S:13215 E:13227 ||| RB
,  ||| S:13227 E:13229 ||| ,
the  ||| S:13229 E:13241 ||| DT
data  ||| S:13241 E:13246 ||| NNS
reported  ||| S:13246 E:13255 ||| VBD
here  ||| S:13255 E:13260 ||| RB
provide  ||| S:13260 E:13268 ||| VB
the  ||| S:13268 E:13272 ||| DT
basis  ||| S:13272 E:13278 ||| NN
for  ||| S:13278 E:13282 ||| IN
future  ||| S:13282 E:13289 ||| JJ
experiments  ||| S:13289 E:13309 ||| NNS
attempting  ||| S:13309 E:13320 ||| VBG
to  ||| S:13320 E:13323 ||| TO
determine  ||| S:13323 E:13333 ||| VB
the  ||| S:13333 E:13337 ||| DT
signal  ||| S:13337 E:13344 ||| NN
transduction  ||| S:13344 E:13357 ||| FW
mechanisms  ||| S:13357 E:13376 ||| FW
whereby  ||| S:13376 E:13384 ||| FW
inflammatory  ||| S:13384 E:13397 ||| FW
agents  ||| S:13397 E:13404 ||| FW
enhance  ||| S:13404 E:13412 ||| FW
sulfur  ||| S:13412 E:13419 ||| FW
mustard  ||| S:13419 E:13435 ||| FW
cytotoxicity ||| S:13435 E:13447 ||| FW
.  ||| S:13447 E:13471 ||| .
Methods  ||| S:13471 E:13498 ||| NNP
Materials  ||| S:13498 E:13518 ||| NNPS
LPS  ||| S:13518 E:13522 ||| NNP
( ||| S:13522 E:13523 ||| -LRB-
Escherichia  ||| S:13523 E:13535 ||| NNP
Coli  ||| S:13535 E:13540 ||| NNP
Serotype  ||| S:13540 E:13549 ||| NNP
0111 ||| S:13549 E:13553 ||| CD
: ||| S:13553 E:13554 ||| :
B4 ||| S:13554 E:13556 ||| CD
)  ||| S:13556 E:13558 ||| -RRB-
and  ||| S:13558 E:13562 ||| CC
PMA  ||| S:13562 E:13576 ||| NNP
( ||| S:13576 E:13577 ||| -LRB-
Phorbol  ||| S:13577 E:13585 ||| NNP
12-Myristate  ||| S:13585 E:13598 ||| NNP
13-Acetate ||| S:13598 E:13608 ||| NNP
)  ||| S:13608 E:13610 ||| -RRB-
were  ||| S:13610 E:13615 ||| VBD
purchased  ||| S:13615 E:13625 ||| VBN
from  ||| S:13625 E:13640 ||| IN
Sigma  ||| S:13640 E:13646 ||| NNP
Chemical  ||| S:13646 E:13655 ||| NNP
Co ||| S:13655 E:13657 ||| NNP
.  ||| S:13657 E:13659 ||| .
St.  ||| S:13659 E:13663 ||| NNP
Louis ||| S:13663 E:13668 ||| NNP
,  ||| S:13668 E:13670 ||| ,
MO ||| S:13670 E:13672 ||| NNP
.  ||| S:13672 E:13674 ||| .
Murine  ||| S:13674 E:13681 ||| NNP
IL-1-beta  ||| S:13681 E:13691 ||| NNP
was  ||| S:13691 E:13705 ||| VBD
obtained  ||| S:13705 E:13714 ||| VBN
from  ||| S:13714 E:13719 ||| IN
Research  ||| S:13719 E:13728 ||| NNP
Diagnostic  ||| S:13728 E:13739 ||| NNP
Inc ||| S:13739 E:13742 ||| NNP
.  ||| S:13742 E:13744 ||| .
( ||| S:13744 E:13745 ||| -LRB-
Flanders ||| S:13745 E:13753 ||| NNP
,  ||| S:13753 E:13755 ||| ,
NJ ||| S:13755 E:13757 ||| NNP
) ||| S:13757 E:13758 ||| -RRB-
.  ||| S:13758 E:13770 ||| .
r-TNF-alpha  ||| S:13770 E:13782 ||| FW
( ||| S:13782 E:13783 ||| -LRB-
human ||| S:13783 E:13788 ||| JJ
)  ||| S:13788 E:13790 ||| -RRB-
was  ||| S:13790 E:13794 ||| VBD
obtained  ||| S:13794 E:13803 ||| VBN
from  ||| S:13803 E:13808 ||| IN
Promega  ||| S:13808 E:13816 ||| NNP
Co  ||| S:13816 E:13829 ||| NNP
( ||| S:13829 E:13830 ||| -LRB-
Madison ||| S:13830 E:13837 ||| NNP
,  ||| S:13837 E:13839 ||| ,
WI ||| S:13839 E:13841 ||| NNP
) ||| S:13841 E:13842 ||| -RRB-
.  ||| S:13842 E:13872 ||| .
Cell  ||| S:13872 E:13877 ||| NN
culture  ||| S:13877 E:13885 ||| NN
and  ||| S:13885 E:13889 ||| CC
treatments  ||| S:13889 E:13910 ||| NNS
RAW264.7  ||| S:13910 E:13919 ||| VBP
murine  ||| S:13919 E:13926 ||| JJ
macrophage-like  ||| S:13926 E:13942 ||| JJ
cells  ||| S:13942 E:13948 ||| NNS
( ||| S:13948 E:13949 ||| -LRB-
American  ||| S:13949 E:13958 ||| NNP
Type  ||| S:13958 E:13973 ||| NNP
Culture  ||| S:13973 E:13981 ||| NNP
Collection ||| S:13981 E:13991 ||| NNP
,  ||| S:13991 E:13993 ||| ,
Rockville ||| S:13993 E:14002 ||| NNP
,  ||| S:14002 E:14004 ||| ,
MD ||| S:14004 E:14006 ||| NNP
)  ||| S:14006 E:14008 ||| -RRB-
were  ||| S:14008 E:14013 ||| VBD
cultured  ||| S:14013 E:14022 ||| VBN
at  ||| S:14022 E:14025 ||| IN
37°C  ||| S:14025 E:14040 ||| CD
in  ||| S:14040 E:14043 ||| IN
a  ||| S:14043 E:14045 ||| DT
humidified  ||| S:14045 E:14056 ||| JJ
incubator  ||| S:14056 E:14066 ||| NNS
( ||| S:14066 E:14067 ||| -LRB-
95 ||| S:14067 E:14069 ||| CD
%  ||| S:14069 E:14071 ||| NN
air  ||| S:14071 E:14075 ||| NN
with  ||| S:14075 E:14080 ||| IN
5 ||| S:14080 E:14081 ||| CD
%  ||| S:14081 E:14083 ||| NN
CO  ||| S:14083 E:14097 ||| NNP
2  ||| S:14097 E:14099 ||| CD
)  ||| S:14099 E:14101 ||| -RRB-
in  ||| S:14101 E:14104 ||| IN
RPMI-1640  ||| S:14104 E:14114 ||| CD
medium  ||| S:14114 E:14121 ||| NN
with  ||| S:14121 E:14126 ||| IN
10 ||| S:14126 E:14128 ||| CD
%  ||| S:14128 E:14130 ||| NN
fetal  ||| S:14130 E:14146 ||| JJ
bovine  ||| S:14146 E:14153 ||| JJ
serum ||| S:14153 E:14158 ||| NN
,  ||| S:14158 E:14160 ||| ,
100  ||| S:14160 E:14164 ||| CD
U ||| S:14164 E:14165 ||| NNP
/ ||| S:14165 E:14166 ||| NNP
ml  ||| S:14166 E:14169 ||| NN
penicillin  ||| S:14169 E:14180 ||| NNS
and  ||| S:14180 E:14184 ||| CC
100  ||| S:14184 E:14188 ||| CD
mg ||| S:14188 E:14190 ||| FW
/ ||| S:14190 E:14191 ||| FW
ml  ||| S:14191 E:14204 ||| FW
streptomycin  ||| S:14204 E:14217 ||| FW
( ||| S:14217 E:14218 ||| -LRB-
GiBcoBRL  ||| S:14218 E:14227 ||| NNP
Grand  ||| S:14227 E:14233 ||| NNP
Island ||| S:14233 E:14239 ||| NNP
,  ||| S:14239 E:14241 ||| ,
NY ||| S:14241 E:14243 ||| NNP
) ||| S:14243 E:14244 ||| -RRB-
.  ||| S:14244 E:14246 ||| .
Adherent  ||| S:14246 E:14255 ||| JJ
cells  ||| S:14255 E:14271 ||| NNS
were  ||| S:14271 E:14276 ||| VBD
subcultured  ||| S:14276 E:14288 ||| VBN
over  ||| S:14288 E:14293 ||| IN
night  ||| S:14293 E:14299 ||| NN
in  ||| S:14299 E:14302 ||| IN
96  ||| S:14302 E:14305 ||| CD
well  ||| S:14305 E:14310 ||| RB
Costar  ||| S:14310 E:14317 ||| JJ
tissue  ||| S:14317 E:14334 ||| NN
culture  ||| S:14334 E:14342 ||| NN
plates  ||| S:14342 E:14349 ||| NN
in  ||| S:14349 E:14352 ||| IN
serum-free  ||| S:14352 E:14363 ||| JJ
RPMI  ||| S:14363 E:14368 ||| NN
with  ||| S:14368 E:14373 ||| IN
0.1 ||| S:14373 E:14376 ||| CD
%  ||| S:14376 E:14378 ||| NN
BSA  ||| S:14378 E:14392 ||| NNP
( ||| S:14392 E:14393 ||| -LRB-
RPMI-0.1 ||| S:14393 E:14401 ||| NNP
% ||| S:14401 E:14402 ||| NN
BSA ||| S:14402 E:14405 ||| NNP
) ||| S:14405 E:14406 ||| -RRB-
.  ||| S:14406 E:14436 ||| .
MTT  ||| S:14436 E:14440 ||| NNP
assay  ||| S:14440 E:14446 ||| NN
for  ||| S:14446 E:14450 ||| IN
determination  ||| S:14450 E:14464 ||| NN
of  ||| S:14464 E:14467 ||| IN
cell  ||| S:14467 E:14482 ||| NN
viability  ||| S:14482 E:14502 ||| VBD
This  ||| S:14502 E:14507 ||| DT
assay  ||| S:14507 E:14513 ||| NN
for  ||| S:14513 E:14517 ||| IN
cell  ||| S:14517 E:14522 ||| NN
viability  ||| S:14522 E:14532 ||| NN
is  ||| S:14532 E:14535 ||| VBZ
based  ||| S:14535 E:14541 ||| VBN
on  ||| S:14541 E:14544 ||| IN
the  ||| S:14544 E:14558 ||| DT
reduction  ||| S:14558 E:14568 ||| NN
of  ||| S:14568 E:14581 ||| IN
3- ||| S:14581 E:14583 ||| NNP
( ||| S:14583 E:14584 ||| -LRB-
4,5-dimethylthiazolyl-2 ||| S:14584 E:14607 ||| NNP
) ||| S:14607 E:14608 ||| -RRB-
-2,5-diphenyltetrazolium  ||| S:14608 E:14643 ||| FW
bromide  ||| S:14643 E:14651 ||| FW
( ||| S:14651 E:14652 ||| -LRB-
MTT ||| S:14652 E:14655 ||| NNP
)  ||| S:14655 E:14657 ||| -RRB-
by  ||| S:14657 E:14660 ||| IN
mitochondrial  ||| S:14660 E:14674 ||| JJ
dehydrogenase  ||| S:14674 E:14688 ||| NN
in  ||| S:14688 E:14691 ||| IN
viable  ||| S:14691 E:14708 ||| JJ
cells  ||| S:14708 E:14714 ||| NNS
to  ||| S:14714 E:14717 ||| TO
produce  ||| S:14717 E:14725 ||| VB
a  ||| S:14725 E:14727 ||| DT
purple  ||| S:14727 E:14734 ||| JJ
formazan  ||| S:14734 E:14743 ||| JJ
product ||| S:14743 E:14750 ||| NN
.  ||| S:14750 E:14752 ||| .
Schweitzer  ||| S:14752 E:14763 ||| FW
et  ||| S:14763 E:14776 ||| FW
al.  ||| S:14776 E:14780 ||| FW
[  ||| S:14780 E:14782 ||| -LRB-
23  ||| S:14782 E:14785 ||| CD
]  ||| S:14785 E:14787 ||| -RRB-
have  ||| S:14787 E:14792 ||| VBP
shown  ||| S:14792 E:14798 ||| VBN
that  ||| S:14798 E:14803 ||| IN
this  ||| S:14803 E:14808 ||| DT
assay  ||| S:14808 E:14814 ||| NN
provides  ||| S:14814 E:14823 ||| VBZ
linearity  ||| S:14823 E:14843 ||| VBN
between  ||| S:14843 E:14851 ||| IN
optical  ||| S:14851 E:14859 ||| JJ
density  ||| S:14859 E:14867 ||| NN
and  ||| S:14867 E:14871 ||| CC
cell  ||| S:14871 E:14876 ||| NN
number ||| S:14876 E:14882 ||| NN
.  ||| S:14882 E:14884 ||| .
This  ||| S:14884 E:14889 ||| DT
assay  ||| S:14889 E:14895 ||| NN
was  ||| S:14895 E:14909 ||| VBD
performed  ||| S:14909 E:14919 ||| VBN
by  ||| S:14919 E:14922 ||| IN
a  ||| S:14922 E:14924 ||| DT
slight  ||| S:14924 E:14931 ||| JJ
modification  ||| S:14931 E:14944 ||| NN
of  ||| S:14944 E:14947 ||| IN
the  ||| S:14947 E:14951 ||| DT
method  ||| S:14951 E:14968 ||| NN
described  ||| S:14968 E:14978 ||| VBD
by  ||| S:14978 E:14981 ||| IN
Wasserman  ||| S:14981 E:14991 ||| NNP
et  ||| S:14991 E:14994 ||| FW
al.  ||| S:14994 E:14998 ||| FW
[  ||| S:14998 E:15000 ||| -LRB-
24  ||| S:15000 E:15003 ||| CD
25  ||| S:15003 E:15006 ||| CD
]  ||| S:15006 E:15008 ||| -RRB-
.  ||| S:15008 E:15010 ||| .
Briefly ||| S:15010 E:15017 ||| RB
,  ||| S:15017 E:15019 ||| ,
at  ||| S:15019 E:15022 ||| IN
the  ||| S:15022 E:15036 ||| DT
end  ||| S:15036 E:15040 ||| NN
of  ||| S:15040 E:15043 ||| IN
each  ||| S:15043 E:15048 ||| DT
experiment ||| S:15048 E:15058 ||| NN
,  ||| S:15058 E:15060 ||| ,
cells  ||| S:15060 E:15066 ||| NNS
cultured  ||| S:15066 E:15075 ||| VBN
in  ||| S:15075 E:15078 ||| IN
96  ||| S:15078 E:15081 ||| CD
well  ||| S:15081 E:15086 ||| RB
plates  ||| S:15086 E:15103 ||| JJ
( ||| S:15103 E:15104 ||| -LRB-
with  ||| S:15104 E:15109 ||| IN
100  ||| S:15109 E:15113 ||| CD
μl  ||| S:15113 E:15116 ||| NN
of  ||| S:15116 E:15119 ||| IN
medium  ||| S:15119 E:15126 ||| NN
per  ||| S:15126 E:15130 ||| IN
well ||| S:15130 E:15134 ||| RB
)  ||| S:15134 E:15136 ||| -RRB-
were  ||| S:15136 E:15141 ||| VBD
incubated  ||| S:15141 E:15151 ||| VBN
with  ||| S:15151 E:15156 ||| IN
MTT  ||| S:15156 E:15170 ||| NNP
( ||| S:15170 E:15171 ||| -LRB-
20  ||| S:15171 E:15174 ||| CD
μl  ||| S:15174 E:15177 ||| NN
of  ||| S:15177 E:15180 ||| IN
5  ||| S:15180 E:15182 ||| CD
μg ||| S:15182 E:15184 ||| CD
/ ||| S:15184 E:15185 ||| CD
ml  ||| S:15185 E:15188 ||| NN
per  ||| S:15188 E:15192 ||| IN
well ||| S:15192 E:15196 ||| RB
)  ||| S:15196 E:15198 ||| -RRB-
at  ||| S:15198 E:15201 ||| IN
37°C  ||| S:15201 E:15206 ||| CD
for  ||| S:15206 E:15210 ||| IN
4  ||| S:15210 E:15212 ||| CD
hours ||| S:15212 E:15217 ||| NNS
.  ||| S:15217 E:15219 ||| .
The  ||| S:15219 E:15233 ||| DT
formazan  ||| S:15233 E:15242 ||| JJ
product  ||| S:15242 E:15250 ||| NN
was  ||| S:15250 E:15254 ||| VBD
solubilized  ||| S:15254 E:15266 ||| VBN
by  ||| S:15266 E:15269 ||| IN
addition  ||| S:15269 E:15278 ||| NN
of  ||| S:15278 E:15281 ||| IN
100  ||| S:15281 E:15285 ||| CD
μl  ||| S:15285 E:15288 ||| NN
of  ||| S:15288 E:15301 ||| IN
dimethyl  ||| S:15301 E:15310 ||| JJ
sulfoxide  ||| S:15310 E:15320 ||| NNS
( ||| S:15320 E:15321 ||| -LRB-
DMSO ||| S:15321 E:15325 ||| NNP
)  ||| S:15325 E:15327 ||| -RRB-
and  ||| S:15327 E:15331 ||| CC
100  ||| S:15331 E:15335 ||| CD
μl  ||| S:15335 E:15338 ||| NN
of  ||| S:15338 E:15341 ||| IN
10 ||| S:15341 E:15343 ||| CD
%  ||| S:15343 E:15345 ||| NN
SDS  ||| S:15345 E:15349 ||| NNP
( ||| S:15349 E:15350 ||| -LRB-
in  ||| S:15350 E:15353 ||| IN
0.01  ||| S:15353 E:15368 ||| NNP
M  ||| S:15368 E:15370 ||| NNP
HCl ||| S:15370 E:15373 ||| NNP
)  ||| S:15373 E:15375 ||| -RRB-
for  ||| S:15375 E:15379 ||| IN
16  ||| S:15379 E:15382 ||| CD
hours  ||| S:15382 E:15388 ||| NNS
at  ||| S:15388 E:15391 ||| IN
37°C ||| S:15391 E:15395 ||| CD
.  ||| S:15395 E:15397 ||| .
The  ||| S:15397 E:15401 ||| DT
dehydrogenase  ||| S:15401 E:15415 ||| JJ
activity  ||| S:15415 E:15434 ||| NN
was  ||| S:15434 E:15438 ||| VBD
expressed  ||| S:15438 E:15448 ||| VBN
as  ||| S:15448 E:15451 ||| IN
the  ||| S:15451 E:15455 ||| DT
absorbance  ||| S:15455 E:15466 ||| NN
( ||| S:15466 E:15467 ||| -LRB-
read  ||| S:15467 E:15472 ||| VBN
with  ||| S:15472 E:15477 ||| IN
a  ||| S:15477 E:15479 ||| DT
Molecular  ||| S:15479 E:15499 ||| NNP
Devices  ||| S:15499 E:15507 ||| NNPS
microplate  ||| S:15507 E:15518 ||| JJ
reader ||| S:15518 E:15524 ||| NN
)  ||| S:15524 E:15526 ||| -RRB-
of  ||| S:15526 E:15529 ||| IN
the  ||| S:15529 E:15533 ||| DT
formazan  ||| S:15533 E:15542 ||| JJ
product  ||| S:15542 E:15550 ||| NN
at  ||| S:15550 E:15553 ||| IN
575  ||| S:15553 E:15567 ||| CD
nm ||| S:15567 E:15569 ||| NNS
.  ||| S:15569 E:15599 ||| .
Dye  ||| S:15599 E:15603 ||| JJ
exclusion  ||| S:15603 E:15613 ||| NN
assay  ||| S:15613 E:15619 ||| NNS
( ||| S:15619 E:15620 ||| -LRB-
PI  ||| S:15620 E:15623 ||| UH
assay ||| S:15623 E:15628 ||| UH
)  ||| S:15628 E:15640 ||| -RRB-
This  ||| S:15640 E:15645 ||| DT
assay  ||| S:15645 E:15651 ||| NN
uses  ||| S:15651 E:15656 ||| VBZ
propidium  ||| S:15656 E:15666 ||| JJ
iodide  ||| S:15666 E:15673 ||| NNS
( ||| S:15673 E:15674 ||| -LRB-
PI ||| S:15674 E:15676 ||| NNP
)  ||| S:15676 E:15678 ||| -RRB-
dye  ||| S:15678 E:15682 ||| NN
to  ||| S:15682 E:15695 ||| TO
differentiate  ||| S:15695 E:15709 ||| VB
live  ||| S:15709 E:15714 ||| JJ
and  ||| S:15714 E:15718 ||| CC
dead  ||| S:15718 E:15723 ||| JJ
cell  ||| S:15723 E:15728 ||| NN
[  ||| S:15728 E:15730 ||| -LRB-
26  ||| S:15730 E:15733 ||| CD
27  ||| S:15733 E:15736 ||| CD
28  ||| S:15736 E:15739 ||| CD
]  ||| S:15739 E:15741 ||| -RRB-
.  ||| S:15741 E:15743 ||| .
Cells  ||| S:15743 E:15759 ||| NNS
that  ||| S:15759 E:15764 ||| WDT
have  ||| S:15764 E:15769 ||| VBP
lost  ||| S:15769 E:15774 ||| VBN
membrane  ||| S:15774 E:15783 ||| JJ
integrity  ||| S:15783 E:15793 ||| NN
cannot  ||| S:15793 E:15800 ||| NNS
exclude  ||| S:15800 E:15808 ||| VBP
PI ||| S:15808 E:15810 ||| NNP
,  ||| S:15810 E:15822 ||| ,
which  ||| S:15822 E:15828 ||| WDT
emits  ||| S:15828 E:15834 ||| VBZ
a  ||| S:15834 E:15836 ||| DT
red  ||| S:15836 E:15840 ||| JJ
fluorescence  ||| S:15840 E:15853 ||| NN
after  ||| S:15853 E:15859 ||| IN
binding  ||| S:15859 E:15867 ||| VBG
to  ||| S:15867 E:15870 ||| TO
cellular  ||| S:15870 E:15889 ||| JJ
DNA  ||| S:15889 E:15893 ||| NN
or  ||| S:15893 E:15896 ||| CC
double  ||| S:15896 E:15903 ||| RB
stranded  ||| S:15903 E:15912 ||| VBN
RNA ||| S:15912 E:15915 ||| NNP
.  ||| S:15915 E:15917 ||| .
After  ||| S:15917 E:15923 ||| IN
each  ||| S:15923 E:15928 ||| DT
experiment ||| S:15928 E:15938 ||| NN
,  ||| S:15938 E:15940 ||| ,
cells  ||| S:15940 E:15956 ||| NNS
were  ||| S:15956 E:15961 ||| VBD
washed  ||| S:15961 E:15968 ||| VBN
with  ||| S:15968 E:15973 ||| IN
PBS  ||| S:15973 E:15977 ||| NNP
and  ||| S:15977 E:15981 ||| CC
incubated  ||| S:15981 E:15991 ||| NN
with  ||| S:15991 E:15996 ||| IN
200  ||| S:15996 E:16000 ||| CD
μl  ||| S:16000 E:16003 ||| NN
of  ||| S:16003 E:16006 ||| IN
RPMI  ||| S:16006 E:16021 ||| NNP
medium  ||| S:16021 E:16028 ||| NN
with  ||| S:16028 E:16033 ||| IN
5  ||| S:16033 E:16035 ||| CD
μg ||| S:16035 E:16037 ||| CD
/ ||| S:16037 E:16038 ||| CD
ml  ||| S:16038 E:16041 ||| JJ
PI  ||| S:16041 E:16044 ||| NN
for  ||| S:16044 E:16048 ||| IN
five  ||| S:16048 E:16053 ||| CD
minutes  ||| S:16053 E:16061 ||| NNS
at  ||| S:16061 E:16064 ||| IN
room  ||| S:16064 E:16079 ||| NN
temperature ||| S:16079 E:16090 ||| NN
.  ||| S:16090 E:16092 ||| .
PI  ||| S:16092 E:16095 ||| NN
fluorescence  ||| S:16095 E:16108 ||| NNS
was  ||| S:16108 E:16112 ||| VBD
measured  ||| S:16112 E:16121 ||| VBN
using  ||| S:16121 E:16127 ||| VBG
a  ||| S:16127 E:16139 ||| DT
Fluostar  ||| S:16139 E:16148 ||| NNP
Galaxy  ||| S:16148 E:16155 ||| NNP
microplate  ||| S:16155 E:16166 ||| JJ
reader  ||| S:16166 E:16173 ||| NN
using  ||| S:16173 E:16179 ||| VBG
an  ||| S:16179 E:16182 ||| DT
excitation  ||| S:16182 E:16203 ||| JJ
wavelength  ||| S:16203 E:16214 ||| NN
of  ||| S:16214 E:16217 ||| IN
485  ||| S:16217 E:16221 ||| CD
nm  ||| S:16221 E:16224 ||| NNS
and  ||| S:16224 E:16228 ||| CC
an  ||| S:16228 E:16231 ||| DT
emission  ||| S:16231 E:16240 ||| JJ
wavelength  ||| S:16240 E:16251 ||| NN
of  ||| S:16251 E:16254 ||| IN
650  ||| S:16254 E:16268 ||| CD
nm ||| S:16268 E:16270 ||| NNS
.  ||| S:16270 E:16272 ||| .
We  ||| S:16272 E:16275 ||| PRP
expressed  ||| S:16275 E:16285 ||| VBD
the  ||| S:16285 E:16289 ||| DT
results  ||| S:16289 E:16297 ||| NNS
as  ||| S:16297 E:16300 ||| IN
the  ||| S:16300 E:16304 ||| DT
percent  ||| S:16304 E:16312 ||| NN
increase  ||| S:16312 E:16321 ||| NN
in  ||| S:16321 E:16334 ||| IN
the  ||| S:16334 E:16338 ||| DT
fluorescence  ||| S:16338 E:16351 ||| NN
of  ||| S:16351 E:16354 ||| IN
treated  ||| S:16354 E:16362 ||| JJ
cells  ||| S:16362 E:16368 ||| NNS
over  ||| S:16368 E:16373 ||| IN
the  ||| S:16373 E:16377 ||| DT
fluorescence  ||| S:16377 E:16400 ||| NN
of  ||| S:16400 E:16403 ||| IN
control  ||| S:16403 E:16411 ||| NN
cells  ||| S:16411 E:16417 ||| NNS
( ||| S:16417 E:16418 ||| -LRB-
no  ||| S:16418 E:16421 ||| UH
treatments ||| S:16421 E:16431 ||| UH
) ||| S:16431 E:16432 ||| -RRB-
,  ||| S:16432 E:16434 ||| ,
i.e. ||| S:16434 E:16438 ||| FW
,  ||| S:16438 E:16440 ||| ,
100  ||| S:16440 E:16444 ||| CD
×  ||| S:16444 E:16446 ||| CD
( ||| S:16446 E:16447 ||| -LRB-
PI  ||| S:16447 E:16461 ||| NNP
treatment  ||| S:16461 E:16471 ||| NN
-PI  ||| S:16471 E:16486 ||| JJ
control  ||| S:16486 E:16494 ||| NN
) ||| S:16494 E:16495 ||| -RRB-
/ ||| S:16495 E:16496 ||| NNP
PI  ||| S:16496 E:16510 ||| NNP
control  ||| S:16510 E:16518 ||| NN
)  ||| S:16518 E:16548 ||| -RRB-
Statistical  ||| S:16548 E:16560 ||| NNP
analyses  ||| S:16560 E:16579 ||| NN
Means  ||| S:16579 E:16585 ||| VBZ
among  ||| S:16585 E:16591 ||| IN
treatments  ||| S:16591 E:16602 ||| NNS
were  ||| S:16602 E:16607 ||| VBD
compared  ||| S:16607 E:16616 ||| VBN
by  ||| S:16616 E:16619 ||| IN
one-way  ||| S:16619 E:16627 ||| JJ
ANOVA  ||| S:16627 E:16643 ||| NNP
followed  ||| S:16643 E:16652 ||| VBD
by  ||| S:16652 E:16655 ||| IN
the  ||| S:16655 E:16659 ||| DT
Scheffe  ||| S:16659 E:16667 ||| JJ
test  ||| S:16667 E:16672 ||| NN
with  ||| S:16672 E:16677 ||| IN
a  ||| S:16677 E:16679 ||| DT
significance  ||| S:16679 E:16692 ||| NN
level  ||| S:16692 E:16698 ||| NN
of  ||| S:16698 E:16711 ||| IN
0.05 ||| S:16711 E:16715 ||| CD
.  ||| S:16715 E:16717 ||| .
In  ||| S:16717 E:16720 ||| IN
both  ||| S:16720 E:16725 ||| PDT
the  ||| S:16725 E:16729 ||| DT
Tables  ||| S:16729 E:16736 ||| NNP
and  ||| S:16736 E:16740 ||| CC
Figures ||| S:16740 E:16747 ||| NNS
,  ||| S:16747 E:16749 ||| ,
means  ||| S:16749 E:16755 ||| VBZ
not  ||| S:16755 E:16759 ||| RB
sharing  ||| S:16759 E:16767 ||| VBG
a  ||| S:16767 E:16779 ||| DT
common  ||| S:16779 E:16786 ||| JJ
letter  ||| S:16786 E:16793 ||| NN
are  ||| S:16793 E:16797 ||| VBP
significantly  ||| S:16797 E:16811 ||| RB
different  ||| S:16811 E:16821 ||| JJ
( ||| S:16821 E:16822 ||| -LRB-
p  ||| S:16822 E:16824 ||| CD
< ||| S:16824 E:16826 ||| SYM
0.05 ||| S:16826 E:16830 ||| CD
) ||| S:16830 E:16831 ||| -RRB-
.  ||| S:16831 E:16843 ||| .
Means  ||| S:16843 E:16849 ||| VBZ
sharing  ||| S:16849 E:16857 ||| VBG
a  ||| S:16857 E:16859 ||| DT
common  ||| S:16859 E:16866 ||| JJ
letter  ||| S:16866 E:16873 ||| NN
are  ||| S:16873 E:16877 ||| VBP
not  ||| S:16877 E:16881 ||| RB
significantly  ||| S:16881 E:16905 ||| RB
different ||| S:16905 E:16914 ||| JJ
.  ||| S:16914 E:16916 ||| .
The  ||| S:16916 E:16920 ||| DT
means  ||| S:16920 E:16926 ||| NNS
and  ||| S:16926 E:16930 ||| CC
standard  ||| S:16930 E:16939 ||| JJ
deviations  ||| S:16939 E:16950 ||| NNS
of  ||| S:16950 E:16953 ||| IN
three  ||| S:16953 E:16969 ||| CD
independent  ||| S:16969 E:16981 ||| JJ
experiments  ||| S:16981 E:16993 ||| NNS
are  ||| S:16993 E:16997 ||| VBP
provided  ||| S:16997 E:17006 ||| VBN
in  ||| S:17006 E:17009 ||| IN
both  ||| S:17009 E:17014 ||| PDT
the  ||| S:17014 E:17018 ||| DT
Figures  ||| S:17018 E:17036 ||| NNS
and  ||| S:17036 E:17040 ||| CC
Tables ||| S:17040 E:17046 ||| NNP
.  ||| S:17046 E:17079 ||| .
Authors ||| S:17079 E:17086 ||| NNP
'  ||| S:17086 E:17088 ||| POS
contributions  ||| S:17088 E:17110 ||| NNS
WLS  ||| S:17110 E:17114 ||| VBP
drafted  ||| S:17114 E:17122 ||| VBN
the  ||| S:17122 E:17126 ||| DT
manuscript  ||| S:17126 E:17137 ||| NN
and  ||| S:17137 E:17141 ||| CC
supervised  ||| S:17141 E:17152 ||| VBD
the  ||| S:17152 E:17156 ||| DT
overall  ||| S:17156 E:17172 ||| JJ
conduct  ||| S:17172 E:17180 ||| NN
of  ||| S:17180 E:17183 ||| IN
the  ||| S:17183 E:17187 ||| DT
research ||| S:17187 E:17195 ||| NN
,  ||| S:17195 E:17197 ||| ,
which  ||| S:17197 E:17203 ||| WDT
was  ||| S:17203 E:17207 ||| VBD
performed  ||| S:17207 E:17217 ||| VBN
in  ||| S:17217 E:17220 ||| IN
his  ||| S:17220 E:17232 ||| PRP$
laboratory ||| S:17232 E:17242 ||| NN
.  ||| S:17242 E:17244 ||| .
MQ  ||| S:17244 E:17247 ||| NNP
carried  ||| S:17247 E:17255 ||| VBD
out  ||| S:17255 E:17259 ||| RP
all  ||| S:17259 E:17263 ||| DT
of  ||| S:17263 E:17266 ||| IN
the  ||| S:17266 E:17270 ||| DT
experimental  ||| S:17270 E:17283 ||| JJ
work  ||| S:17283 E:17288 ||| NN
in  ||| S:17288 E:17299 ||| IN
this  ||| S:17299 E:17304 ||| DT
study  ||| S:17304 E:17310 ||| NN
and  ||| S:17310 E:17314 ||| CC
performed  ||| S:17314 E:17324 ||| VBD
the  ||| S:17324 E:17328 ||| DT
statistical  ||| S:17328 E:17340 ||| JJ
analyses ||| S:17340 E:17348 ||| NNS
.  ||| S:17348 E:17350 ||| .
MS  ||| S:17350 E:17361 ||| NNP
( ||| S:17361 E:17362 ||| -LRB-
along  ||| S:17362 E:17368 ||| RB
with  ||| S:17368 E:17373 ||| IN
WLS ||| S:17373 E:17376 ||| NNP
)  ||| S:17376 E:17378 ||| -RRB-
conceived  ||| S:17378 E:17388 ||| VBD
of  ||| S:17388 E:17391 ||| IN
the  ||| S:17391 E:17395 ||| DT
study ||| S:17395 E:17400 ||| NN
,  ||| S:17400 E:17402 ||| ,
participated  ||| S:17402 E:17415 ||| VBD
in  ||| S:17415 E:17426 ||| IN
the  ||| S:17426 E:17430 ||| DT
study  ||| S:17430 E:17436 ||| NN
design ||| S:17436 E:17442 ||| NN
,  ||| S:17442 E:17444 ||| ,
and  ||| S:17444 E:17448 ||| CC
provided  ||| S:17448 E:17457 ||| VBD
continuous  ||| S:17457 E:17468 ||| JJ
evaluation  ||| S:17468 E:17479 ||| NN
of  ||| S:17479 E:17482 ||| IN
the  ||| S:17482 E:17494 ||| DT
experimental  ||| S:17494 E:17507 ||| JJ
data ||| S:17507 E:17511 ||| NNS
.  ||| S:17511 E:17513 ||| .
All  ||| S:17513 E:17517 ||| DT
authors  ||| S:17517 E:17525 ||| NNS
read  ||| S:17525 E:17530 ||| VBP
and  ||| S:17530 E:17534 ||| CC
approved  ||| S:17534 E:17543 ||| VBD
the  ||| S:17543 E:17547 ||| DT
final  ||| S:17547 E:17561 ||| JJ
manuscript ||| S:17561 E:17571 ||| NN
.  ||| S:17571 E:17588 ||| .
